medtronic
fy17
integrated
performance
report

ceo letter                                3   responsible supply management                 26
company overview                          4      supplier quality management                26
   about our company                      4      responsible supply management              26
   organizational profile                 4      supplier diversity                         27
   global footprint                       5   ethics in sales and marketing                 29
sustainability risks and opportunities    6      ethical business conduct                   29
   our sustainability material issues     6      customer data security                     30
   sustainability management              6   working responsibly our company              31
   reducing sustainability risk           7
                                              governance and engagement                     32
   creating opportunities                 8
                                                 corporate governance                       32
economic contributions to society         9
                                                 ethical workplace                          33
   financial performance                  9
                                                 public policy                              34
   return to shareholders                10
                                                 stakeholder engagement                     34
   compensation and wages                11
                                              operations                                    35
   taxes                                 11
                                                 our management approach                    35
   expenditures                          11
                                                 operational footprint                      36
   acquisitions and investments          12
                                                 energy use and ghg emissions               36
   financial assistance                  12
                                                 managing waste                             37
   philanthropy                          12
                                                 water                                      38
value to society our priorities         15   employees                                     39
access                                   16      global workforce                           39
   therapy innovation                    16      investing in our workforce                 39
   economic value                        17      employee engagement                        40
   expanding global access               18      inclusion and diversity                    40
product quality                          21      employee compensation                      41
   responsibility for quality            21      safety and wellness                        41
   maintaining quality facilities        22      data summary                               42
   product use and performance           22   about this report                             44
   clinical trials                       23      scope and data                             44
   preclinical research                 24      assurance and forwardlooking statements   44
product stewardship                      25      further information                        44
   our approach                          25   integration index                             45
                                                 integrated reporting at medtronic          45
                                              nongaap financial measures                   47

ceo letter


for more than 55 years we have pursued our mission to alleviate pain                                   donating 1018 million to charitable causes through corporate
restore health and extend life our values have been instrumental in                                      cash contributions giving through the medtronic foundation
earning the trust of partners customers and employees as a result                                      product donations and employee volunteering
70 million people benefited from medtronic technology services and
                                                                                                         investing more than 76 million in employee training and
solutions this year  more than ever before
                                                                                                           development programs
this achievement comes at a time when healthcare systems face mounting
                                                                                                         achieving four out of five of our 2020 environmental performance
economic pressures leaving millions unable to benefit from modern
                                                                                                           goals including reductions in energy emissions waste and water
medical technologies as a global healthcare leader medtronic is an integral
part of the solution to addressing the industrys biggest challenges                                   looking ahead we will continue to work toward key business and
                                                                                                        sustainability objectives that will help us transform the way healthcare
by extending our existing therapies into emerging markets we are
                                                                                                        is delivered innovation and partnership will be critical to our success
increasing access for more people and contributing to revenue growth
                                                                                                        innovative products and processes will help us bring effective treatments
in fy17 revenue in emerging markets grew in the doubledigit range1
                                                                                                        to more people and our partnerships with healthcare providers
our total annual revenue increased approximately 5 percent1 globally
                                                                                                        governmental organizations and others will help to multiply our efforts
as we continued our focus on achieving our mission
                                                                                                        to improve patients lives around the world
sustainability is critical to our business performance helping us mitigate
                                                                                                        our mission will remain our guide to meeting the challenges of the future
risk enhance quality increase efficiency and drive innovation in this
                                                                                                        i look forward to sharing our progress in the coming year
annual integrated report we outline performance across our most
important sustainability issues global access to care product quality
product stewardship responsible supply management and ethics in
sales and marketing
we continue to innovate to meet the healthcare needs of a growing
global population im proud of the many successes we achieved in                                       omar ishrak
fy17 including                                                                                        chairman and chief executive officer
 investing 22 billion in research and development representing
   74 percent of net sales
 launching medtronic labs a new initiative designed to deliver
   financially sustainable businesses that expand access and reduce
   health inequality in emerging markets
 investing 1397 million in capacity building and training for medical
   professionals and 226 million in patient education



1 figures represent comparison to prior year on a constant currency constant week basis nongaap                                                                  ceo letter  3

company
overview


medtronic is improving healthcare for more people in more                     organizational profile
places than ever before we are among the worlds largest                     medtronic has four operating segments cardiac and vascular minimally
medical technology services and solutions companies we                      invasive therapies restorative therapies and diabetes each group is
are guided by our mission to alleviate pain restore health and               separated into business divisions that deliver a wide range of medical
extend life helping us transform millions of lives every year                technologies therapies services and solutions in fy17 we realigned the
                                                                               divisions within the restorative therapies group to include spine brain
about our company                                                              therapies pain therapies and specialty therapies

we deliver innovative services and solutions to hospitals physicians
clinicians and patients in approximately 160 countries our goal is to be      medtronic operating segments
a trusted partner in the transformation of healthcare through meaningful        fy17 total sales and business divisions
innovation and by expanding global access to therapies our three               total net sales 297 billion
strategic priorities are
                                                                                operating segments                                    fy17 net sales
 therapy innovation see access                                              and business divisions                                 billion

 globalization see expanding global access                                  cardiac and vascular group                            105
 economic value see economic contributions to society                        cardiac rhythm and heart failure
                                                                                 coronary and structural heart
                                                                                 aortic and peripheral vascular
 medtronic fy17 snapshot                                                       minimally invasive therapies group                    99
                                                                                 surgical solutions
 number of employees                                                91000       patient monitoring and recovery

 number of countries in which we operate                approximately 160       restorative therapies group                           74
                                                                                 spine
 number of locations                                                   260       brain therapies
                                                                                 specialty therapies
 research and development spend                                 22 billion     pain therapies

 number of patents                                                53000       diabetes group                                        19
                                                                                 intensive insulin management
 patients served                                                 70 million      nonintensive diabetes therapies
                                                                                 diabetes service and solutions

                                                                                                                                       company overview  4

global footprint

fy17 net sales to external customers by region  million
total net sales 29710
                              greater china
                              1589 5
                                                             annual research and development spend  million
            asia paciÔ¨Åc
            3443 12


                                                               fy15                                                                1640

                                                               fy16                                                                                          2224

               europe
                                                               fy17                                                                                        2193
               middle east
               and africa
               6739 23         americas
                                                              fy15 based on medtronic fiscal year as reported and reflects the partial year contribution of the covidien
                                    17939 60            transaction that closed on jan 16 2015




                                                                                                                                             company overview  5

sustainability risks
and opportunities


by fulfilling our mission we are transforming peoples lives               additional material issues identified through the review include corporate
making our greatest contribution to society we bring further                governance device security financial strength philanthropy postmarket
social and environmental benefits by promoting high sustainability           surveillance stakeholder engagement talent and trial data
standards across our operations products and supply chain                 we explain our approach to each priority sustainability issue in this
doing business responsibly and sustainably helps us to mitigate              integrated report and our gri supplement
risks reduce operating costs and enhance our reputation as an
employer and trusted partner                                                sustainability management
                                                                             the ssc develops strategy and oversees sustainability performance
our sustainability material issues                                           risk engagement disclosure and recognition the committee meets
we focus on the sustainability issues that are most important to our         at least twice a year and includes leaders from business functions across
business and our stakeholders we identified our material issues in fy14     the company our chief financial officer is the sscs executive champion
by consulting internal and external stakeholders including healthcare
                                                                             we take implementation of social and environmental responsibilities
providers policymakers and investors in fy17 our sustainability
                                                                             seriously and manage these issues in our daily operations through the
steering committee ssc reviewed our strategy on each of our priorities
                                                                             following functions
our sustainability priorities are
                                                                              environmental health safety and sustainability ehss
 access to care working with health systems around the world sharing
                                                                              ethics and compliance
   technologies services resources and expertise to remove barriers to
   affordable treatment of chronic diseases                                   global communications
 product quality ensuring that our products and services clearly comply    global quality
   with the highest standards of safety and reliability
                                                                              global strategy
 product stewardship minimizing the lifecycle footprint of our products
   and packaging through design innovations                                   human resources

 responsible supply management collaborating with our supply chain         investor relations
   to develop longterm relationships that enhance product quality           legal
   worker rights and environmental protection
                                                                              regulatory
 ethics in sales and marketing leading our industry as a trusted
   partner with a commitment to ensure responsible business practices in      philanthropy
   marketing communication and promotion of our products and services
                                                                              procurement


                                                                                                                      sustainability risks and opportunities  6

reducing sustainability risk
we manage sustainability risks as part of our overall risk management strategy to see how these fit within our most significant business risks see the risk
factors included in our form 10k and 10q filings with the us securities and exchange commission we cannot guarantee that even the most exhaustive
efforts will fully mitigate or prevent impact on our business success
the table below outlines our top sustainability risk areas and how we manage them


    sustainability risk area                  how we manage risk



    evolving ethical social and             our government affairs human resources ehss and procurement groups monitor relevant regulations in
    environmental regulations                 global markets while our legal and compliance teams oversee compliance with those regulations we engage
                                              industry organizations and regulators to educate them about our industry perspectives and prepare for
                                              potential and pending regulation



    failure to meet customer                  we design our programs to meet or exceed customer requirements on all aspects of sustainability including
    sustainability requirements               quality access environment labor practices and responsible supply management we further enhanced
                                              requirements for global conduct related to human rights and labor standards in fy16 when we established
                                              our responsible supply management function in fy17 we developed the foundational elements of the
                                              program including the release of our global human rights and labor standards policy



    increasing costs from endof             we incorporate criteria into our development processes that consider a products environmental impacts
    productlife obligations                  throughout its lifecycle our commitment to product stewardship includes efforts to reclaim and recycle
                                              products at the end of their useful life through our sustainable technologies business we also aim to reduce
                                              the cost of endoflife obligations by minimizing the use of hazardous materials



    reputational damage from                  our office of ethics and compliance trains employees to comply with our code of conduct and we have clear
    unethical behavior                        processes to report and act on any concerns we also offer additional compliance training for employees in
                                              certain roles to mitigate the risk of corruption and misconduct




                                                                                                                              sustainability risks and opportunities  7

ensuring business continuity                                                 meeting customer expectations
our business continuity management program proactively identifies and        our healthcare partners want to work with businesses that share their
manages risks that could result in disruptions to our operations or supply   values we must demonstrate strong credentials on ethical environmental
chain key focus areas are                                                  and social issues to meet customer requirements win new business and
                                                                             remain a partner of choice
 business continuity planning developing strategies designed
   to ensure that we can continue to operate and meet demand in
   adverse circumstances                                                     driving business efficiency
                                                                             setting goals on energy use emissions waste generation and water use
 crisis management and mobilization coordinating responses                helps us minimize our environmental impacts  and our operational costs
   in case of crises
                                                                             our 2020 sustainability goals using a fy13 baseline are to reduce
 emergency response establishing procedures to keep people and
   assets safe and to minimize environmental impact in emergencies            energy use per unit of revenue by 15 percent
 it response and recovery planning responses to deal with any              greenhouse gas ghg emissions per unit of revenue by 15 percent
   failures in technology and reinstate affected infrastructure to
                                                                              nonregulated waste per unit of revenue by 15 percent
   support business continuity
                                                                              regulated waste per unit of revenue by 10 percent
our crisis management teams follow a robust protocol to manage issues
effectively and coordinate responses across the company if any issues        water use per unit of revenue by 10 percent
arise that could have significant impact on the business our teams notify
the medtronic global command center and our corporate crisis filter         for information on progress toward our sustainability goals see operations
team determines an appropriate response the corporate crisis team
updates the executive committee regularly on progress                       responding to investors
                                                                             investors recognize strong performance in sustainability as an indicator
creating opportunities                                                       of forwardlooking management and proactive risk mitigation medtronic
                                                                             has been included in the dow jones sustainability index since 2008 and the
our sustainability program is not only about managing risk it also helps
                                                                             ftse4good index since 2001 we submit environmental data to the cdp
us generate new business opportunities strengthen relationships
                                                                             annually we also report on indicators set by the global reporting initiative
with customers improve efficiency and meet investor customer and
                                                                             gri and sustainability accounting standards board in our gri supplement
regulatory requirements

leading in valuebased healthcare
traditional healthcare systems are based on payments for products and
services rather than results this can lead to rising healthcare costs and
suboptimal patient outcomes we advocate for a valuebased healthcare
vbhc system in which payment is based on the ability of products and
services to improve patient outcomes relative to their cost
our current vbhc offerings fall under three categories therapy
optimization episodic bundles and chronic care management for more
information about our vbhc strategy and approach see economic value


                                                                                                                      sustainability risks and opportunities  8

economic contributions
to society


our contribution to society is linked to the success of our company as we grow our business we                          all nongaap generally
reach more patients contribute more to local economies and deliver consistent returns for our                           accepted accounting
shareholders we make important economic contributions through the jobs we create the taxes we                           principles financial measures
                                                                                                                          referenced throughout
pay and the capital investments we make our corporate donations and grants channeled through
                                                                                                                          this report are identified
the medtronic foundation and other charitable giving provide further support to improve access to                        as nongaap measures
healthcare for underserved communities                                                                                   for reconciliation of each
                                                                                                                          nongaap measure to the
financial performance                                                                                                     most directly comparable
strong financial performance ensures that we can deliver consistent growth and returns while also contributing to         measure determined using
the local economies where we live and work in fy17 we made meaningful progress in our core growth strategies            us gaap please see the
of therapy innovation globalization and economic value as a result we delivered record revenue of 297 billion      section titled nongaap
an increase of 3 percent on a reported basis and approximatively 5 percent on a constant currency constant week          financial measures at
basis compared to the previous year                                                                                      the back of this report

for more information on our financial performance see our 2017 10k

revenue growth
our strategy for revenue growth is based on an unmatched pipeline of products and services and our global reach
in diversified markets extending our existing therapies into emerging markets represents the greatest opportunity
for our business
we are working to accelerate growth in emerging markets through public and private partnerships and by optimizing
our distribution channels in fy17 revenue in emerging markets grew 7 percent or in the double digits on a nongaap
constant currency constant week basis




                                                                                                                        economic contributions to society  9

                                                                                                                return to shareholders
                                                                                                                in fy17 we had 56 billion in free cash flow nongaap and returned
                                                                                                                55 billion to shareholders net of share issuances we paid a total of
                                                                                                                24 billion in cash dividends at a rate of 172 per share we continued
                                                                                                                to be included in the sp 500 dividend aristocrats index marking our
net sales by operating segment and business  million                                                         39th consecutive year of dividend increases
revenue growth as reported
                                                                                                                dividend per share
    fy15                                                         19
                                                                  6 nongaap                                 fy15                                                122
    fy16                                                                                     42
                                                                                              7 nongaap     fy16                                                             152

    fy17                                                                                       3                fy17                                                                      172
                                                                                               3 nongaap


0            5000          10000          15000         20000          25000          30000               dividend payout ratio
                                                                                                                 fy15                      30
cardiac and vascular                                 restorative therapies
                                                                                                                 fy16                           36
      cardiac rhythm and heart failure                    spine

      coronary and structural heart                       brain therapies
                                                                                                                 fy17                             39
                                                                                                                 calculated by taking the current annualized dividend per share 184 and dividing it by the prior
      aortic and peripheral vascular                      specialty therapies                                   fiscal year nongaap diluted earnings per share


                                                          pain therapies
minimally invasive therapies                                                                                    total payout ratio
      surgical solutions                             diabetes                                                    fy15                                           55
      patient monitoring                                  diabetes
      and recovery                                                                                               fy16                                                          72

 fy15 based on medtronic fiscal year as reported and reflects the onequarter contribution of the               fy17                                                                       86
covidien transaction which closed on jan 26 2015

  figure represents comparison to prior year on a constant currency constant week basis                        the payout ratio for fy16 and fy17 include a contribution from a 5 billion incremental share
                                                                                                                repurchase commitment
                                                                                                                
                                                                                                                  calculated by taking the current annualized dividend per share 184 and dividing it by the prior
                                                                                                                fiscal year nongaap diluted earnings per share




                                                                                                                                                                         economic contributions to society  10

compensation and wages                                                                                expenditures
we are investing in talent for our manufacturing commercial and rd                                 we make investments in infrastructure manufacturing capabilities and
operations globally in fy17 we had more than 91000 employees in                                    technology that allow us to grow our business in fy17 these capital
approximately 160 countries where possible we hire and develop local                                expenditures totaled nearly 13 billion
talent leading to job creation in communities near our operations
                                                                                                      capital expenditures  million
we spent 85 billion in total compensation in fy17 including 50 billion in
                                                                                                      additions to property plant and equipment
direct salary and wages and an additional 602 million in retirement benefits
                                                                                                          fy15                          571
 employee compensation  million
                                                                                                          fy16                                                     1046
                                                      fy15            fy16            fy17
 total compensation                                  5614            8057            8486          fy17                                                               1254
 salary and wages                                     3169            4634            5006
 retirement benefit plans                             433              584              602
                                                                                                      operating costs and other expenditures are essential to running our business
 employees                                            85000           88000           91000     through these expenses we also enhance our economic contribution and
 all amounts are based on actual exchange rate
                                                                                                      positive impacts on society for instance communities in which we operate

  total compensation includes salary and wages incentives overtime severance pay payroll taxes   can benefit from our salaries and wages research and development rd
retirement benefits auto allowance and other benefits
 the fy15 compensation data contained in this table represents medtronic operations excluding      outlays sales general and administrative expenses and taxes
covidien however the employees data for this same period includes covidien

   fy16 contained 53 weeks while other years only contain 52 weeks
                                                                                                      medtronic expenses  million
taxes
we also contribute to the communities and countries in which we operate                                   fy15
through the taxes we pay these include income real estate sales and use
payroll excise and valueadded taxes
                                                                                                          fy16
in fy17 we had 578 million in income tax provisions resulting in a
162 percent nongaap nominal tax rate on a gaap basis our global
                                                                                                          fy17
effective rate was 126 percent

                                                                                                      0             5000            10000            15000            20000           25000            30000


                                                                                                             income tax                                           cost of products sold

                                                                                                             selling general                                    other
                                                                                                             and administrative

                                                                                                             research and development


                                                                                                       fy15 based on medtronic fiscal year as reported and reflects the partialyear contribution of the covidien
                                                                                                      transaction which closed on jan 26 2015
                                                                                                      
                                                                                                        includes the following expenses interest expense net amortization of intangible assets acquisitionrelated
                                                                                                      items certain litigation charges net restructuring charges net special charges gains

                                                                                                                                                                economic contributions to society  11

acquisitions and investments                                                     divestitures
we support business growth by investing in the development of our                when appropriate divestitures provide the opportunity to refocus
markets products and services we also seek opportunities for strategic        our business and portfolio on our strategic priorities on july 29 2017
acquisitions and investments that will help us enhance our role as a             we completed the sale of our patient care deep vein thrombosis
healthcare leader                                                               and nutritional insufficiency businesses for 61 billion in cash these
                                                                                 businesses were located within the patient monitoring and recovery
approach to acquisitions                                                         division of our minimally invasive therapies group and included 17
                                                                                 dedicated manufacturing facilities
we pursue acquisitions that bring new technology strategic skills
capabilities and expertise to medtronic our approach aligns with our
strategy to provide a broad range of therapies to restore patients health       financial assistance
and extend lives through positive clinical outcomes we target firms that        government agencies and other stakeholder groups occasionally provide
support our core growth strategies  therapy innovation economic                financial incentives including tax relief tax credits and grants other
value and globalization  and will produce strong financial returns            direct incentives include subsidies benefits and awards these financial
specifically we look for tuckin acquisitions that will deliver midteens       incentives aim to attract and support longterm investments in specific
riskadjusted returns and demonstrate clear economic value to our               regions or for disease states that align with medtronics business strategy
business acquisitions in fy17 included
 heartware international inc on august 23 2016 our cardiac and            philanthropy
   vascular group acquired heartware international inc heartware
                                                                                 our philanthropic efforts  alongside our products core business
   heartware develops and manufactures miniaturized implantable heart
                                                                                 and mission  aim to expand access to healthcare and build healthy
   pumps to treat certain populations of patients suffering from advanced
                                                                                 communities globally
   heart failure total consideration for the transaction was approximately
   11 billion                                                                 in fy17 we donated approximately 19 percent of our pretax profits
                                                                                 we manage these philanthropic contributions through our corporate
 smith  nephews gynecology business on august 5 2016 our
                                                                                 charitable giving our business divisions and the medtronic foundation
   minimally invasive therapies group acquired smith  nephews
                                                                                 see next page more information about the medtronic foundation is
   gynecology business this expands and strengthens our minimally
                                                                                 available here
   invasive surgical offerings and further complements its existing global
   gynecology business total consideration for the transaction was              we disclose all donations made to us customers or organizations
   approximately 350 million                                                   affiliated with them annually on our charitable donations registry
                                                                                 to view the guidelines governing our philanthropic contributions by
approach to investments                                                          the businesses see charitable donations guidelines
in addition to making acquisitions we invest in infrastructure capabilities   to learn more about medtronic product donations see access
and initiatives within our existing business that accelerate the pace and
breadth of innovation this enables us to gain competitive advantage and
enhance benefits for patients for example in fy17 we invested in a new
nonintensive diabetes therapies ndt facility in plymouth minnesota
it will serve as the global headquarters for ndt where dedicated teams will
focus on product development for addressing type 2 diabetes




                                                                                                                            economic contributions to society  12

                                                                                                                    rhd action launched in fy16 aims to cultivate a global movement
 philanthropy  million
                                                                                                                      to end rheumatic heart disease rhd in vulnerable populations
                                                                 fy15           fy16             fy17                led by a coalition of core organizations the initiative seeks to unite
                                                                                                                      and empower the global rhd community by sharing technical advice
 medtronic foundation giving                                     470           482            400               advocacy support and policy insights in fy17 rhd action focused
 corporate cash contributions                                   313           496            434               its efforts in uganda to decentralize screening and diagnosis improve
                                                                                                                      referrals and strengthen the capacity of existing medical facilities
 product donations           
                                                                 115           168            168               that treat rhd it also assessed needs to inform the expansion of the
 volunteering                                                                                 16                program in tanzania in fy18
 philanthropic contributions as a                                19            23             19
 percentage of global pretax profits                                                                           community wellbeing
 fy15 does not include legacy covidien data
                                                                                                                   the medtronic foundation provides health access grants for underserved

  the significant increase in corporate cash contributions and product donations from fy15 to fy16 is the result   populations in the communities where our employees have a significant
of the covidien integration
 calculated with an hourly rate of 2356 provided by independent sector fy17 was the first year we tracked     presence these twoyear grants are awarded to organizations that
the value of volunteering
                                                                                                                   expand access to healthcare for people with chronic diseases address
                                                                                                                   persistent or emerging health challenges and build partnerships to
medtronic foundation global health programs
                                                                                                                   promote collaboration in fy17 the foundation distributed grants worth
through its global health programs the medtronic foundation aims to                                               a total of 51 million to more than 40 organizations in 37 communities
establish sustainable healthcare solutions in communities around the                                               around the world
world its global health programs focus on increasing access to healthcare
for underserved populations by working with local and global partners                                             disaster relief grants from the foundation help to fund emergency
                                                                                                                   healthcare in the wake of a crisis and support rebuilding of damaged
in fy17 the foundation contributed to three flagship programs                                                    infrastructure in the long term medtronic also provides product donations
                                                                                                                   to support disaster relief efforts and encourages employees to donate
 heartrescue applies best practice to reduce premature mortality from
                                                                                                                   funds and volunteer their time
   acute cardiovascular events to best serve the unique needs of each
   community the program combines localized patient empowerment
   engagement with frontline health workers and policy advancement                                                disaster relief  millions
   in fy17 the us heartrescue consortium expanded to 16 states
   covering nearly 80 million people heartrescue china and heartrescue                                                                                            fy15           fy16              fy17
   india completed the second year of a fiveyear international expansion                                           medtronic foundation                           06            08              07
   project plans are also under way to establish the program in brazil                                            disaster relief
 healthrise aims to enable accurate diagnosis and successful                                                      fy15 does not include legacy covidien data
   management of diabetes and cardiovascular disease for underserved
   populations the program enhances care provision by working with
   frontline health workers improving the efficiency of referral systems
   and empowering patients in selfmanagement strategies in fy17
   healthrise addressed barriers to care in communities in brazil india
   south africa and the united states




                                                                                                                                                                           economic contributions to society  13

promoting volunteering
we encourage employees to participate in our medtronic foundation                employee community engagement
philanthropic efforts through volunteering and employee giving                                                                              fy15              fy16            fy17
we kick off each new fiscal year with a monthlong volunteering drive            project 6
project 6 that encourages employees to get involved in their local
communities in fy17 nearly 15000 employees in 48 countries                        volunteers                                              8880              19800            14900
volunteered a total of approximately 62000 hours the five teams with               total volunteer hours                                   29000             64800            62000
the highest participation greatest impact and most unique approach won
a 10000 grant from the medtronic foundation for their chosen charity              countries                                               35                 44                48
                                                                                     employeeled projects                                   274                512               462
the foundation also donates funds to nonprofits for every 25 hours
that an individual employee volunteers throughout the year more than            volunteer grants
1000 employees participated in fy17 raising more than 500000                   volunteer grants                                         786                968               1106
the medtronic foundation matches employee contributions to                          volunteer grants  raised                              515000           484000          553000
approved charities dollarfordollar through global matching grants
in fy17 employees donated approximately 14 million leading to a               global matching grants
total contribution of more than 27 million when matched                           employee contributions  million                      243              149             142
the foundations bakken invitation award recognizes individuals who                medtronic match  million                           20                174           131
with the help of medical technology  have overcome health challenges
                                                                                 fy15 does not include legacy covidien data
and now give back to their communities in fy17 the award honored 15           
                                                                                  the decrease in number of volunteers and volunteer hours from fy16 to fy17 is primarily a result of a significant
individuals from seven countries their inspiring stories can be read online   campaign around volunteering during the integration of covidien in fy16 leading to increased participation
                                                                                 covidien data for the period januarymarch 2016 is included in the fy16 employee contributions full fy16
                                                                                covidien data was not included due to the timing of covidiens integration into the medtronic workday system
                                                                                
                                                                                   the foundation held a 21 matching campaign in fy16 resulting in a greater dollar amount matched than
                                                                                employee donations
                                                                                 medtronic matches are made on a 11 basis up to 500 as a result matches are not the same amount as
                                                                                employee contributions




                                                                                                                                               economic contributions to society  14

value to
society
our
priorities




             15

access



medical technology and therapies are essential tools in the
                                                                                                                                 annual rd spending
treatment of noncommunicable diseases our core business
delivers positive outcomes for more patients and invests in new                                                                                                                       fy15                fy16                fy17
solutions for unserved health needs                                                                                             rd spend  million                                1640               2224              2193
lack of healthcare infrastructure and limited resources mean                                                                    fy15 based on medtronic fiscal year as reported and reflects the partial year contribution of the covidien
essential care and treatment are inaccessible to millions of                                                                   transaction that closed on jan 26 2015

people we aim to create wider access to quality affordable
healthcare our business model focuses on improving patient                                                                    introducing new products
outcomes and reaching more people while taking into account                                                                    many of our new products and therapies are designed to treat patients
the economic realities of specific markets                                                                                    directly enabling positive health outcomes and a better quality of life
by demonstrating the value of new products and making them                                                                     others use data to help physicians provide better guidance or to support
                                                                                                                               more effective management of specific conditions
widely accessible we are growing our business and delivering our
mission to improve health outcomes for people around the world                                                                our new products therapies and data platforms launched in fy17 include
                                                                                                                                micratm transcatheter pacing system the miniaturized pacemaker is
therapy innovation                                                                                                                93 percent smaller than its conventional counterparts it can be implanted
our continued investment in research and clinical trials is delivering                                                            through a noninvasive procedure and is selfcontained within the heart
innovative new therapies that improve patients lives                                                                            micra was approved for use in the united states by the fda in april 2016
                                                                                                                                minimed 670g insulin pump the worlds first hybrid closedloop
research and clinical trials                                                                                                      system that can selfadjust to help keep sugar levels in range it is
a robust innovation pipeline is critical to our success our global research                                                      fda approved for use in the united states2
and development rd prioritizes unserved health needs including
                                                                                                                                stealthstationtm s8 our most advanced surgical navigation system
conditions that disproportionately affect people in emerging markets
                                                                                                                                  that combines hardware software tracking algorithms image data
we take promising innovations through to clinical trials to establish their
                                                                                                                                  merging and specialized instruments to help guide during surgical
safety and effectiveness
                                                                                                                                  procedures it received fda 510k clearance in march 2017
in fy17 we invested 22 billion in rd 74 percent of net sales and
                                                                                                                                in fy17 medtronic became the first company to receive fda approval
launched 75 new clinical trials read about our responsible approach to
                                                                                                                                  for our suite of cardiac devices and leads able to be scanned in both
clinical trials in product quality
                                                                                                                                  3 and 15 tesla magnetic resonance imaging mri machines patients
                                                                                                                                  using these devices can now receive mri scans on any part of the body
                                                                                                                                  which may not have been possible previously

2 the minimed 670g insulin pump is indicated for type 1 diabetes patients age 14 and over prescription required warning may not be safe for children under age 7 or those requiring less than 8 units of insulin
per day selfadjusts refers to the auto mode function some user interaction required individual results may vary for detailed boxed warning and important safety information see here                                     access  16

read more about products receiving fda clearance and approval and              we follow a proprietary sevenstep vbhc framework to ensure we develop
ce mark approval in fy17 at the medtronic newsroom                            valuebased business models built around clear measurable patient
                                                                               outcomes in fy17 we created a new data science function to facilitate
in addition to our own focus on innovation we also invest in or
                                                                               collaboration within and outside medtronic in developing enterprisewide
acquire other medical technology companies to expand our offering
                                                                               data systems that support our vbhc initiatives
to patients read about other partnerships and acquisitions in
economic contributions to society                                             with many conditions or treatments we have an opportunity to improve
                                                                               patient outcomes and reduce costs at the same time for example type
                                                                               1 diabetes costs healthcare systems around the world billions of dollars
economic value
                                                                               every year nearly 500000 children under the age of 15 globally live with
we continually look for efficiencies to improve the affordability of our       type 1 diabetes and longterm complications include kidney disease
products and therapies and enhance economic value across global                amputation and stroke
healthcare systems this includes offering a variety of pricing models
such as volume pricing or rebate options for hospitals adaptive pricing for   our diabeter clinic network based in the netherlands offers a solution
treating longterm conditions and a range of programs to assist new and       for improving patient outcomes and reducing costs using a vbhc model
existing patients we pursue efficiency gains in tandem with improving         the diabeter clinics are currently the best performing of their kind in
the effectiveness of interventions and the number of patients achieving        the country with 55 percent of patients under age 18 achieving target
positive health outcomes                                                      blood glucose concentrations diabeter also achieves a lower rate of
                                                                               hospitalization among clinic patients leading to a reduction in direct
                                                                               annual patient costs of 86 percent
valuebased healthcare
the majority of current healthcare systems base payment on the volume          our experiences with programs such as diabeter inform our continued
of procedures performed traditional payment and delivery models have          development of vbhc models for a wide range of treatments
produced treatment costs that are unsustainable for many healthcare
systems we believe there must be a fundamental shift in the way               managed services
healthcare is delivered globally  toward valuebased healthcare vbhc       through medtronic integrated health solutions we form relationships
in a vbhc system payment for products and services is based on their          with healthcare providers around the world  helping them to achieve
ability to improve patient outcomes relative to their cost this means         their goals for access cost and highquality care we administer units
sharing direct accountability for delivering meaningful results               facilities and clinics on their behalf with a focus on catheterization labs
                                                                               and hospital operating rooms benefits include an increase in lab capacity
leaders from across our business divisions regions and functions            between 25 and 35 percent
including clinical healthcare economics policy reimbursement and legal
experts  comprise our global vbhc council launched in january 2016          in fy17 we formed a collaboration with university hospitals cleveland
the council is responsible for accelerating our vbhc vision deepening our     in the united states to define new models of efficient and outstanding
knowledge and facilitating the sharing of best practices within medtronic    care delivery in catheterization and electrophysiology laboratories at
under the direction of the global vbhc council we are establishing            uh cleveland medical center a key focus is increasing lab capacity and
councils within our regions to further local knowledge and action             creating an optimized environment where the clinical staff can focus on
                                                                               care delivery medtronic helps implement advancements and also provides
                                                                               onsite staff to manage nonclinical operations such as scheduling
developing valuebased models
                                                                               materials management and room turnover
investment and innovation are essential to achieve the shift to a vbhc
system we are creating new business models that will enable us to take
the lead in driving industrywide transformation


                                                                                                                                                    access  17

telehealth                                                                          a stateoftheart hub hospital is at the center offering specialist
enabling patients who require longterm care to stay in their homes rather          intervention from highly trained physicians the spokes consist of
than be admitted to a healthcare facility can improve quality of life increase     healthcare centers in surrounding communities together they offer
service efficiency and reduce costs a 2016 study showed that monitoring           complete coordinated care with improved patient convenience and
patients remotely can yield savings of 8375 per patient each year3               economies of scale a welldefined patient pathway and referral system is
                                                                                    an important part of the model our patient pathway innovation approach
medtronic care management services provides remote monitoring systems               offers a systematic way to characterize the current care pathway identify
for patients with chronic conditions or for followup after acute care              barriers to access and develop workable solutions for a given location
admissions and surgical procedures mobile or tabletop monitoring platforms         the result is a set of consistent highquality diagnostic and treatment
collect biometric and symptom data triggering a clinical review if necessary      protocols clearly supported by clinical evidence
patients can access our patient advocacy and support services should they
need additional advice from an experienced staff member we currently offer         in fy17 as part of our hub  spoke approach we continued our work with
more than 20 different programs for patients with single or multiple diseases      abraaj capitals global healthcare fund this work focuses on improving
                                                                                    healthcare access primarily in africa and the indian subcontinent by
in fy17 we launched beacon a new service for highrisk heart failure              reducing the gap between supply and demand for health services in
patients who have medtronic icd and cardiac resynchronization therapy               addition medtronic entered into several new hub  spoke partnerships
crt devices by combining data from the patients device with symptoms            with a variety of health system organizations  including private equity
and biometrics beacon enables providers to evaluate early intervention for         firms academics and startups developing innovative healthcare
patients at risk of heart failure                                                  solutions  to deploy hub  spoke models in africa

expanding global access                                                             medtronic labs
we continually look for new ways to expand our treatments and presence              removing barriers to healthcare access and reducing health inequality in
to serve more people in more places around the world rather than taking            emerging markets requires an understanding of local context and priorities
a single global approach we develop our solutions to reflect market needs         medtronic labs is our response to this challenge launched in fy17 it is
this enables us to tailor access initiatives to suit the specific infrastructure   an evolution of our global health initiative and seeks to deliver financially
economics and health priorities of a given location                               sustainable businesses structured for impact and scale medtronic labs
                                                                                    draws on the expertise and knowledge of our employees to develop locally
in certain emerging markets we employ a hub  spoke strategy to                    appropriate business models and provide ambitious ideas for expanding
increase efficiency and accessibility of care see below for underserved          healthcare access
populations in those markets where the disparity between healthcare
needs and access is greatest we develop solutions through initiatives              one of the medtronic labs programs akoma pa aims to help patients
such as medtronic labs outlined at right                                          and clinicians in subsaharan africa manage hypertension more efficiently
                                                                                    in ghana nearly 30 percent of the population has hypertension yet only
read more about the medtronic foundations global health programs                   28 percent of those affected can control it adequately through
in philanthropy                                                                    pharmacological management and lifestyle modifications akoma pa offers
                                                                                    enhanced management and access to treatment combining a proprietary
hub  spoke models                                                                  mobile application with support from local pharmacists and clinicians by
the hub  spoke model of healthcare delivery is designed to maximize                providing tailored management plans this novel model offers significant
efficiency and improve patient access where resources are limited the              opportunity to reduce the burden of chronic care management for clinicians
model offers a strategic approach to healthcare infrastructure  an                 patients and health systems based on our learning from akoma pa we plan
efficient integrated system designed to support longterm health and               to roll out a wider hypertension program  empower health  in fy18
care needs

3 home pilot study undertaken by geneia                                                                                                              access  18

understanding access needs                                                       in china we are collaborating with the chengdu municipal government
for our access initiatives to be appropriate and effective we must              to invest in a manufacturing facility for stateoftheart diabetes
understand evolving patient needs and market opportunities we do                management technology the aim is to expand access to essential
this through our patient access acceleration paa methodology                  interventions for the growing number of people with diabetes in china
a consistent approach to identifying and tackling access needs in any            and nearby countries
location paa includes four steps
                                                                                 capacity building
 quantify treatment needs
                                                                                 simply expanding patient access to products and therapies is not
 identify barriers to care                                                     enough to deliver transformative change local infrastructure needs to
                                                                                 support effective interventions and healthcare providers and patients
 prioritize barriers to care
                                                                                 must have the skills and knowledge to offer and understand specific
 formulate strategies to tackle barriers                                       treatment options

through our patient access solutions pas consulting service we partner        through our hub  spoke model described above we create capacity in
with hospitals around the world to identify access needs and barriers and       healthcare systems by developing infrastructure and investing in the skills
implement appropriate local solutions in fy17 our pas group completed          of healthcare professionals we also partner with local healthcare providers
10 consulting engagements in three countries we focused these activities        to deliver infrastructure changes through medtronic integrated health
in the asia pacific region enabling us to build intensive expertise and         solutions see managed services
integration with local healthcare services within a single region
                                                                                 in fy17 we invested 1397 million in capacity building and training for
                                                                                 medical professionals and 226 million in patient education specific
partnering with others                                                           activities included
collaboration is an essential component of our efforts to reach more
                                                                                  launch of medtronic impact in our europe middle east and africa
patients around the world we partner with a range of stakeholders to
                                                                                    region as part of our drive toward vbhc models we are introducing
tackle access needs including
                                                                                    a novel approach to healthcare education and development medtronic
 healthcare providers as well as governmental and nongovernmental                 impact extends beyond traditional product and procedure training
   organizations to enhance ontheground delivery                                  offering an extensive range of topics to the entire spectrum of
                                                                                    healthcare professionals online and offline programs will be developed
 peer companies to develop new technologies and therapies                         and delivered through a network of collaborations with worldclass
 universities and academics to promote thought leadership                         healthcare institutions our ambition is for medtronic impact to reach
   and research                                                                     more than 500000 healthcare professionals in the next five years

cardiovascular disease causes more deaths in russia than any other chronic        enhancing clinical training in africa in partnership with stellenbosch
disease yet only 7 percent of affected patients receive stents each year          university south africa we launched a new clinical training laboratory
in fy17 we partnered with the renova group russias leading private               for healthcare professionals the lab offers a realworld training
business group to establish a new joint venture known as stentex this joint      environment for cuttingedge procedures  including use of high
venture aims to enable local production of medtronic catheter balloons and          definition surgical microscopes imageguided navigation equipment
stents for the treatment of acute coronary syndrome  with the potential            and keyhole surgery endoscopes the facility hosts professionals from
to support thousands of patients through lifesaving interventions                 across africa and has the capacity to train up to 1200 people in its first
                                                                                    year alone




                                                                                                                                                      access  19

 medtronic innovation centers mics mic training centers offer
   specialist facilities for healthcare professionals to enhance their
   knowledge and skills the center in shanghai china hosted nearly
   7000 physicians for training sessions on surgical technique in osong
   south korea we delivered training for more than 1000 physicians
   including programs for trainee surgeons to gain handson experience
   with medtronic technologies and products
 capacity building through patient access solutions pas our
   pas group examines capacity as part of its consulting engagements
   in fy17 pas interventions resulted in the development of a tool to
   identify patient groups needing better access in kazakhstan as well
   as improved clinician capacity at a facility in australia
 partnership with the world stroke organization wso through
   our continued partnership with the wso we developed new programs
   focused on increasing stroke awareness among patients and healthcare
   professionals we sponsored the wso road map for quality stroke
   care which provides guidance on stroke care for local healthcare
   providers and clinical groups we also collaborated with the wso on
   the delivery of awarenessraising activities in china and india

 healthcare capacity building
                                                            fy15     fy16    fy17
 education for medical professionals                        1088   1524   1397
  million
 education for patients  million                         187    203    226
 medical professionals reached                              50796   64233   52193
 excludes mitg patient monitoring and recovery business



product donations
to further improve patient access to essential treatments we made
168 million in product donations in fy17
read more in economic contributions to society




                                                                                       access  20

product quality



patients rely on our products to be safe and effective we deploy
                                                                             how medtronics global quality and supply management strategies
controls at every stage of the value chain  from clinical research to       support our business strategy
postmarket analysis  so patients and physicians can be confident
in the quality we deliver we reinforce our commitment to product            business strategy needs                              quality imperatives

quality through regular training for our employees and suppliers

responsibility for quality
                                                                                    therapy                     product                effective and          mindset of
we protect patients health through our unwavering focus on product                 innovation                  superiority            efficient              excellence
                                                                                                                                       compliance
excellence our commitment to quality helps us effectively treat patients                                      providing
                                                                                                                products of            complying with
                                                                                                                                                              ingraining a proactive
                                                                                                                                                              and patientcentric
reduce reputational risk maintain trust in our business and improve                                           highest quality        applicable             quality culture
                                                                                                                and reliability        regulations            and quality talent
operational efficiency                                                                                                                efficiently            management

patients are at the heart of our global quality strategy our programs                              suppliers         supply management imperatives
                                                                                                    are
are designed to ensure that medtronic products are of high quality and             globalization   partners
above all safe
we expect our people to take individual responsibility and demonstrate
leadership on quality our culture of quality training and communications                                       quality and            functional             supplier
                                                                                                                service                excellence             performance
focuses on one key message quality begins with me reinforcing four                                            excellence             optimized and          create
fundamental behavior expectations                                                  economic                    proactive supplier     scalable process       competitive
                                                                                    value                       engagement             capabilities           advantage

 put the patient first
 be courageous
 strive to prevent issues before they arise
 hold each other accountable
in fy17 we extended our quality begins with me training to more than
200 suppliers we also help suppliers build their own systems and
capabilities to align with our quality requirements see responsible
supply management for more information




                                                                                                                                                          product quality  21

employees worldwide complete an annual quality training certification        we assess our quality management systems through our global compliance
this focuses on product quality regulatory compliance good                  oversight program medtronic corporatewide assessment for regulatory
documentation practices and continual improvement in fy17                  excellence mcare this helps us maintain consistent quality and
97 percent of employees completed the training                               regulatory compliance across the business and enhance our readiness
                                                                              to comply with new regulatory requirements in fy17 we assessed and
our design reliability manufacturability drm program integrates safety
                                                                              implemented improvements at 40 of our facilities through mcare
quality and reliability throughout our product development process
engineers can simulate how products are used in the real world to better
understand and predict performance through our first time quality ftq       maintaining quality facilities
methodology we train our manufacturing employees to see the potential
for error develop strong controls and identify where improvements have                                                                            fy15          fy16           fy17
the biggest impact on product quality
                                                                               external regulatory inspections                                      168          244           284
we use the medtronic operating system mos to embed quality into              at medtronic sites globally
production by applying lean six sigma principles a teambased system
                                                                               external regulatory inspections                                      92          89           93
for achieving continual improvement we also use the leading international
                                                                               globally which resulted in no findings
standard for medical device quality system management iso 13485
                                                                               average findings per external                                        018         030          018
in fy17 we expanded our drm mos and ftq processes to all new                regulatory inspection
product development and manufacturing sites we also expanded our
supplier quality initiatives by rolling out trainings and ftq programs to      average findings per fda inspection                                  048          144          073
contract manufacturers and suppliers
                                                                               mcare assessments and                                                28            37             40
                                                                               supported improvements
maintaining quality facilities                                                 numbers are restated from 2015 integrated report due to the inclusion of regional inspections
                                                                              
                                                                                numbers are restated from 2016 integrated report due to an internal validation process that identified a
external regulatory agencies review and monitor our performance on            missing inspection
quality and compliance with regulations every year their assessments
help us better understand regulatory priorities and identify areas
where we can further enhance our policies procedures and processes         product use and performance
we share what we learn across the business through our inspection             we monitor the performance of our products in use and collect data on
knowledge management process and implement improvements at                    quality and patient outcomes through postmarket surveillance
our facilities worldwide
                                                                              we capture critical data on products through our postapproval clinical
in fy17 there were 284 regulatory inspections at medtronic sites            surveillance process which draws on a network of partner hospitals health
of these 93 percent resulted in no findings our goal is to maintain an      systems physicians clinics governments and thirdparty databases this
average of 05 or fewer findings per inspection in fy17 we achieved this    process covers north america europe and latin america and continues
goal with an average of 018 findings per inspection                         to expand as our business grows
in the subset of inspections conducted by the fda we received                medtronic also funds indepth postmarket clinical studies on specific
073 findings per inspection meeting our goal of 10 or fewer findings       therapies and product lines to support further improvements
per us fda inspection




                                                                                                                                                                     product quality  22

enhancing postmarket surveillance
                                                                                    fy17 fda class i recalls and medwatch safety alert product list for
postmarket surveillance helps us fulfill our commitment to prioritize              medtronic devices
patient outcomes and offer valuebased healthcare we collaborate with
global regulators and industry stakeholders to enhance our postmarket              fda class i recalls               1 pipeline classic marathon
surveillance techniques and methods                                                                                     ultraflow xcelerator

more than 1900 clinical professionals across medtronic work to develop                                               2 heartware ventricular assist device
                                                                                                                         hvad system controller
and standardize models to measure and improve patient safety and clinical
outcomes we are exploring new methods to obtain valuable information                                                 3 ht70 ventilator
on enabling product use at lower cost without compromising quality or                                                4 stratamr
regulatory compliance
                                                                                                                      5 synchromed ii bolus priming software card
we collaborate with our customers to help improve our products and
services we collect and manage feedback using a global complaint                   fda medwatch                      1 stratamr adjustable valves and shunts
handling system                                                                    safety alerts for                 2 capnostream 20 patient monitor
                                                                                    human medical                        battery packs
                                                                                    products database
productrelated regulatory actions                                                                                    3 capnostream 20p patient monitor
we implement corrective actions swiftly and effectively when regulatory                                                  battery packs
or field safety issues are identified including initiation of voluntary product                                      4 synchromed ii and synchromed el
recalls we aim to understand and remedy the root cause of any problem                                                   implantable drug infusion pumps
and have systems in place to prevent recurrence                                                                      5 medtronic neurovascular products
the fda classifies product recalls with a numerical designation i ii or iii
                                                                                    the fda issues medwatch safety alerts to provide the public with new safety information about a product
to indicate the relative degree of health hazard class i is the most serious     this includes some actions that have been classified as recalls by the fda
in fy17 five medtronic products were subject to class i recalls see tables
more detail on the nature of these recalls can be found on the fda list of
                                                                                   clinical trials
device recalls website
                                                                                   clinical trials test the safety and efficacy of our products before they go on
 product use and performance                                                       the market we are committed to conducting all our clinical trials in accordance
                                                                                   with relevant laws and regulations and with our own code of conduct global
                                                 fy15       fy16       fy17        business conduct standards policy and clinical trials principles we are also
                                                                                   committed to following international guidelines for clinical research such as
 open fda consent decree for                     1          1          1
                                                                                   the international conference on harmonization  world health organization
 productrelated regulatory actions
                                                                                   good clinical practice standards and iso 141552011
 open fda warning letters for                    3          1          2
 productrelated regulatory actions
 open fda warning letters                        2          0          1
 resolved during the year
 fda class i recalls                             6          4          5




                                                                                                                                                                        product quality  23

we collaborate with organizations working to advance the development               preclinical research
of clinical standards and support related educational engagements
                                                                                   regulatory requirements sometimes necessitate animal research and
see table below
                                                                                   testing for our products for more than 30 years medtronic has been a
                                                                                   leader in pioneering innovative approaches to reduce the use of animals
 clinical standard development and
 education engagements                                                             medtronic senior principal scientist mike wolf has worked diligently to
                                                                                   develop innovative animalfree alternatives for blood interaction tests
 organization            fy17                                                      over half of medtronics products come into contact with patient blood
 clinical trials         our senior vice president and chief scientific           consequently the iso 109934 standard on blood interaction testing
 transformation          clinical and regulatory officer serves on the            is a key guideline for the preclinical evaluation of our devices due to
 initiative ctti       ctti executive committee                                 his efforts a revised iso 109934 standard was published in april 2017
                                                                                   it includes new nonanimal testing methods and serves as the medical
 association for         medtronic is involved in the aamis us and              device industrys global guidance document for the selection of blood
 the advancement         international work our employees participate             interaction tests
 of medical              in more than 120 aami committees and working
 instrumentation         groups and hold 11 leadership positions including        an important international validation study on alternatives to animal
 aami                  the rotating chair of the board of directors             testing for skin irritation was completed in fy17 the original research
 international           medtronic maintains an active presence in the             was put forward by the distinguished medtronic toxicologist kelly
 medical device          imdrf our subject matter experts serve as                coleman the followup validation study conducted at 20 labs and
 regulators forum        industry representatives on imdrf initiatives we         sponsored by the iso technical committee confirmed that synthesized
 imdrf                 also supported and participated in the pilot of the       human skin is an acceptable replacement for the existing rabbit skin
                         imdrfs medical device single audit program              irritation test the findings of the study will be submitted in fy18 and
                                                                                   will support the planned iso 10993 standard on human skin cellbased
 medical device          our chief medical officer serves on the board of          irritation testing
 innovation              directors of mdic a publicprivate partnership
 consortium mdic       which aims to advance regulatory science in the           our policy regarding the use of animals requires that animals only be
                         medical device industry                                  used in research activities where there are no acceptable alternatives
                                                                                   this includes research that contributes significantly to patient welfare
transparency and open data                                                         as well as work specifically mandated by regulatory agencies in order to
                                                                                   ensure patient safety or efficacy all such activities are conducted only
sharing data from clinical trials helps medtronic and the broader scientific       after approval from the institutional animal care and use committee
community to deliver benefits for patients in the long term it also
supports our commitment to maintaining patient safety and scientific               when it is necessary to use animals in research we are committed to
integrity when performing clinical trials                                         treating them respectfully and humanely by taking every measure to
                                                                                   safeguard their welfare this includes minimizing pain suffering distress
we publicly disclose information on clinical trials as required through          and harm we work with scientists veterinary surgeons and other experts
the clinical trials registry available at clinicaltrialsgov this registry and   to refine trials to develop the best possible approach
results database details the purpose eligibility requirements locations
and status of the applicable clinical trials we sponsor we also publish           we are committed to meeting all relevant standards and requirements
findings in peerreviewed scientific and medical journals and collaborate          for animalrelated research and testing set by the association for
with external researchers and institutions                                        assessment and accreditation of laboratory animal care the fda
                                                                                   and the us department of agricultures animal welfare act



                                                                                                                                              product quality  24

product stewardship



from pacemakers to insulin pumps our products improve and                   packaging design and innovation
save patients lives while our products offer clear benefits for            sourcing sustainable packaging materials and cutting our overall packaging
people and society their manufacture use and disposal can                 needs reduces environmental impacts production costs and waste
impact the environment we work to minimize our products                    in fy17 we launched a sustainable packaging working group that will
environmental impact reducing energy and resources used                     establish processes and programs to promote assess and measure
and waste created at every stage of the product lifecycle                   sustainability in our packaging design in fy18 we aim to refine our
                                                                             sustainable packaging guidelines identify targets and track progress
                                                                             on sustainable packaging projects across the business
our approach
customers increasingly expect us to demonstrate strong product               endoflife management
stewardship across the lifecycle through our environmental health
safety and sustainability ehss program we require the implementation    an important part of our product stewardship strategy is understanding
of product stewardship initiatives throughout medtronic helping us better   managing and reducing the impact of products at the end of their usable life
meet these expectations                                                     we aim to capture value from used products and divert them from landfill

to reduce the environmental footprint of our products from the start our    in fy17 our sustainable technologies business diverted more than 308
engineers and scientists have started incorporating ehss guidelines         metric tons mt of used medical devices our nellcor business alone
as they research develop and design new products we consider              collected and recycled more than 2700 mt of used medical sensors
environmental impacts related to manufacturing and the materials used        that would otherwise have gone to landfill through other reclamation
in our products and their packaging when products reach the end of their    programs we collected more than 54 mt of precious metals  such
usable life we reclaim materials for reuse where possible                  as gold silver platinum titanium and palladium  from products like
                                                                             pacemakers defibrillators and neurostimulators
we monitor regulatory changes globally and implement practices to
comply with all applicable local regulations including the european
union directives on restriction of hazardous substances rohs and
registration evaluation authorization and restriction of chemicals
reach and california proposition 65 in fy17 we began transitioning
to compliance with the european unions new medical device regulation
mdr which will replace the previous medical device directive and active
implantable medical device directive




                                                                                                                                    product stewardship  25

responsible supply
management


our mission supports a culture of citizenship purpose and                        supplier quality management
responsibility we hold ourselves accountable to promote human                     healthcare partners and patients expect us to deliver flawless products
rights environmental stewardship and ethical behavior and we                    and therapies our product quality is critical to our reputation and future
extend the same expectations to our suppliers                                     success to achieve the highest quality standards we focus not just on
                                                                                   our own operations see product quality but also on our management
suppliers are integral to the delivery of the products therapies and             of suppliers
technologies we need to improve patient outcomes to maintain the
quality and reliability of our supply chain we aim to forge longstanding         we provide protocols tools training and support to help suppliers meet
relationships with suppliers that share our commitment to high standards          our quality standards including
we have more than 73000 suppliers in 129 countries in fy17 we spent              continuous improvement opportunities through training and development
nearly 12 billion with our suppliers globally
                                                                                    participation in our design reliability manufacturability drm process
                                                                                      which ensures standardized product performance
 supply chain spend  million
                                                                                    our supplier quality excellence manual that all suppliers are required
                                                fy15      fy16        fy17           to follow
 australia                                      549      527       737       in fy17 medtronic was recognized in the gartner healthcare supply chain
 canada                                         774      1398      1490      top 25  an acknowledgment of leading companies in demanddriven
                                                                                   supply chain management
 china                                          1432     2525      2819
 france                                         933      2475      1856      for more information about how we manage quality in our finished
                                                                                   products see supplier quality on our website
 germany                                        1609     2333      2200
 ireland                                        1535     1951      2059
                                                                                   responsible supply management
 israel                                         103      175       211
                                                                                   we expect our suppliers and contractors to behave ethically abide by
 japan                                          1007     1380      1649      applicable laws uphold the human rights of workers ensure a safe and
 mexico                                         552      1280      1519      healthy working environment and use environmentally responsible
 netherlands                                    1297     1799      1849      practices the mission of our responsible supply management program
                                                                                   is to
 singapore                                      314      938       1269
                                                                                    uphold human rights and labor standards in our supply chain
 switzerland                                    1396     1806      1911
 united states                                  47553   82568    84987     reduce our environmental impact globally and locally
 total for locations listed                     59054   101155   104556    enhance medtronics reputation
 total spend                                    67079   115435   119275
                                                                                                                               responsible supply management  26
 fy15 does not include legacy covidien data

in fy17 we introduced global supplier standards that outline the minimum        conflict minerals
social ethical and environmental requirements our suppliers must               the us doddfrank act requires companies to disclose the use of
comply with these standards will become part of our selection criteria for      conflict minerals originating from the democratic republic of congo and
new suppliers in fy18 we will begin monitoring compliance against the          neighboring countries where the proceeds of mining have been linked
standards with an initial focus on suppliers in highrisk countries in cases   to armed conflict we support and work to comply with regulations as
of serious noncompliance with our standards we reserve the right                detailed in our conflict minerals policy
to terminate supplier contracts
                                                                                 where minerals covered by this regulation are used in our products we
agents and contractors working with medtronic must comply with the               expect suppliers to comply with this law and uphold responsible sourcing
medtronic global code of conduct we investigate all reported violations         practices we reference conflict minerals requirements in supplier
and take appropriate action where necessary including terminating               agreements and purchase order terms and conditions we also perform
agreements with contractors in addition our global human rights and            annual due diligence by following the oecd guidance on conflict minerals
labor standards policy applies to all medtronic suppliers service providers     including surveying suppliers and collecting data
including thirdparty labor agencies and business partners
                                                                                 we participate in industrywide forums on conflict minerals such as the
responsible supply management best practices are integrated in our               ethical sourcing forum marcus evans conflict minerals conference and
purchasing decisions we train our supply management teams to work               conflictfree sourcing initiative our conflict minerals program leader
with suppliers to help them improve labor standards in fy17 we launched        julia litvak was named in the 2017 top 100 conflict minerals influence
and expanded our labor standards assurance system to better monitor              leaders by assent compliance an independent compliance services firm
labor issues within our operations and those of our suppliers
                                                                                 medtronics fy17 conflict minerals report is published on the sec website
we track how many of our core suppliers produce sustainability reports
as an indicator of their public commitment to social and environmental
responsibility our fy17 survey found that 34 percent of our top 208             supplier diversity
suppliers produce a sustainability report of these 10 percent publicly state   we are committed to supporting diverse suppliers including small
sustainability goals on their website we will continue to monitor our core      businesses as well as businesses owned by women minorities lgbt
suppliers and encourage them to make public sustainability commitments          members veterans and people with disabilities this commitment is
for more information about our supply chain policies procedures and            set out in our us supplier diversity policy in fy17 approximately
best practices see responsible supply management on our website                35 percent of our us supplier spend was with small and diverse
                                                                                 companies we also encourage our tier 1 suppliers to track and report
                                                                                 their spend with diverse businesses
materials of concern
where materials of concern are used in our products or packaging we             our supplier diversity team supplier diversity steering committee
require suppliers to manage these responsibly and in line with regulatory        and executive management team oversee our supplier diversity program
requirements such as the european union directives on restriction of            we promote inclusive sourcing through employee training business unit
hazardous substances rohs and registration evaluation authorization          annual plans and sponsorship of organizations that develop and promote
and restriction of chemicals reach and california proposition 65              small and diverse suppliers in the us in fy17 99 percent of sourcing
see product stewardship                                                       and supply chain management teams in the us completed our supplier
                                                                                 diversity elearning training
                                                                                 medtronic was recognized by diversityincs 2017 top 50 list honoring
                                                                                 leading companies that support workforce diversity inclusion
                                                                                 management and supplier diversity



                                                                                                                           responsible supply management  27

 us diverse supply chain spend by category  million
                                                                    fy15                                 fy16                                 fy17
                                                                     us              us              us             us              us             us
                                                                    spend              spend              spend             spend              spend             spend

 small business                                                     1102             299              21229          325              17969          281
 veteranowned business                                             497              14               826             13               791             12
 minorityowned business enterprise                                 1490             40               1928            30               2790            43
 womenowned business enterprise                                    831              23               1237            19               1390            21
 the diversity table includes only us addressable spend for fy17 addressable spend was approximately 63 billion exclusions from this total employeerelated benefits
health insurance taxes royalties and others

  fy15 data was prior to the covidien acquisition




                                                                                                                                                                                 responsible supply management  28

ethics in sales
and marketing


earning the confidence of our stakeholders and partners is key to         this training is also part of the orientation process for individuals joining
our continued business success to maintain their trust we must          medtronic as senior leaders and in other highrisk roles
be honest and transparent in our product information we must also        distributors dealers and certain other third parties also complete our
eliminate any potential conflicts of interest between employees           anticorruption training we support and monitor thirdparty distributors
and healthcare professionals in our sales and marketing activities       working on our behalf through our distributor compliance program
                                                                          in fy17 we launched a new distributor code of conduct and trained
     guiding policies and principles
                                                                          93 percent of our distributors on this code before entering or renewing a
      global business conduct standards policy                           contract we conduct due diligence to assess the potential for corruption and
       includes our global anticorruption policy                       our contracts require distributors to implement their own anticorruption
                                                                          programs in some markets we are expanding our own direct sales
      code of conduct
                                                                          infrastructure to reduce our reliance on thirdparty distributors decrease
      code of ethics for senior financial officers                       the risk of corruption and improve customer service
      code of business conduct and ethics                                approximately 220 experts fulltime equivalent support compliance with
       for members of the board of directors                              our anticorruption policies worldwide we also consult regulators on our
      medtronic donations                                                anticorruption measures and employ several former us department of
                                                                          justice prosecutors in leadership roles at medtronic
ethical business conduct                                                  in fy17 medtronic was not subject to any fines or settlements related to
the medtronic code of conduct and related policies inform the way we      noncompliance with anticorruption laws
interact with healthcare professionals and how we market our products
our office of ethics and compliance oversees monitors and implements     countering corruption
accompanying policies and programs
                                                                                                                                                   fy15        fy16     fy17
countering corruption                                                      employees supporting anticorruption efforts                            223          223      220
conflict of interest is a recognized risk in our industry eliminating     fulltime employee equivalents
potential conflicts particularly those related to sales interactions      thirdparty distributors receiving                                      87          88      93
between employees and healthcare professionals is a priority             anticorruption training
all employees must comply with our global anticorruption policy          thirdparty distributors receiving                                      64        27   25
global business conduct standards and applicable external laws           onsite monitoring
regulations policies and procedures mandatory annual training on        fy15 data does not include legacy covidien operations
                                                                          
                                                                            restated from 2015 and 2016 integrated report due to internal validation process
our code of conduct reinforces these requirements customerfacing         restated from 2016 integrated report due to internal validation process
employees complete additional anticorruption training every two years

                                                                                                                                                 ethics in sales and marketing  29

responsible marketing to customers and patients                                       customer data security
each business unit is responsible for making sure products are promoted               medtronic relies on data to make our products and therapies effective
accurately and appropriately in line with industry guidelines and                     our customers and patients expect us to keep their data secure this
government laws and regulations when marketing directly to healthcare                responsibility remains a high priority for medtronic the global security
providers we follow an internal code of conduct and advameds voluntary              office and security steering committee oversee our security program
code of ethics on interactions with health care professionals                        ensuring we have policies in place designed to protect this information
                                                                                      we continually look for ways to strengthen our program and to address
we have a comprehensive program in place to help ensure our marketing
                                                                                      evolving threats including cyberthreats the design of our information
practices comply with our own ethical policies and external regulations
                                                                                      security management controls is based on recognized standards such as
as part of this program we monitor thousands of transactions annually for
                                                                                      the national institute of standards and technology and iso 27001
sales and marketing risks such as antikickback bribery and corruption
in fy17 we updated 24 training modules that educate employees and                    a key tenet of the security program includes mandatory security training
external faculty on appropriate product promotion practices medtronic                for employees and contractors with a special focus on those who
was not subject to any fines or settlements related to allegations of                 handle or have access to sensitive data in addition medtronic launched
improper marketing or sales of products in fy17                                      medtroniccomsecurity in november 2016 a disclosure website that
                                                                                      enables customers physicians patients and other interested parties
 responsible marketing to customers and patients                                      to submit inquiries about medical device security matters our security
                                                                                      teams conduct thorough investigations across relevant departments to
                                                           fy15    fy16     fy17     respond to inquiries about product vulnerabilities
 number of fines or settlements                            2        0        0        we actively engage with outside organizations third parties and experts
 related to allegations of improper                                                   to assist us in ensuring continuous improvement with our security program
 marketing or sales of products                                                      in order to address the evolving threat landscape and meet or exceed
 marketing and sales employees                             13944   14409   14899   external best practice standards these include informationsharing
 trained in product promotion                                                         bodies such as the national health information sharing and analysis
                                                                                      center the medical device innovation safety and security consortium
 fy15 data does not include legacy covidien operations

  fines noted represent the year the fine was paid                                   regulators and government agencies our customers and other medical
                                                                                      device manufacturers we also contribute to the development of product
                                                                                      and cybersecurity standards globally
ethical interactions with healthcare professionals
we promote integrated healthcare systems by working with healthcare
professionals to develop innovative solutions our guiding principles
ensure our interactions with these partners are founded on achieving
the best outcomes for patients and eliminating any potential for conflicts
of interest
we support industry initiatives to make information about payments to
healthcare professionals publicly available we disclose payments made to
physicians and teaching hospitals in the countries where this is required by
law in the united states this information is published on the us centers
for medicare and medicaid services open payments website we also
comply with related regulatory reporting requirements
for more information on our approach to physician collaboration
see our website
                                                                                                                                     ethics in sales and marketing  30

working
responsibly
our company




               31

governance
and engagement


we expect all of our employees to demonstrate a strong                       diversity in our leadership helps us reflect the needs of our varied
commitment to ethical behavior through their attitude and                    stakeholders including patients partners employees and communities
actions creating an ethical workplace culture starts with the               twentyfive percent of our board members are women and 25 percent
                                                                             represent minority groups
board of directors and ceo who set companywide expectations
for strong governance and integrity our commitment to                       if the nominating and corporate governance committee identifies a need
integrity underpins our interactions with external stakeholders              to replace a current member of the board fill a vacancy or expand the size
and partners as we collaborate to drive meaningful sustainable              of the board it considers candidates from a variety of sources including
change in the global healthcare system                                      thirdparty search firms that assist with identifying evaluating and
                                                                             conducting due diligence on potential director candidates
corporate governance                                                         potential candidates are evaluated based on criteria established in our
the medtronic board and executive leadership guide our approach              governance principles these criteria include business experience and
to corporate governance and transparency  practices that are                skills judgment honesty and integrity the ability to commit sufficient time
fundamental to the success of our business they oversee policies            and attention to board activities and the absence of potential conflicts
and procedures that support our mission safeguard the interest of           with medtronics interests additional factors considered include diversity
our company and shareholders and ensure employees understand what           with respect to background viewpoint skills experience community
is expected of them the board is also deeply involved in developing our     involvement and input from other members of the board the full board
corporate strategy and they are responsible for reviewing and approving     then chooses a nominee after considering the recommendations and
medtronics annual strategic plan                                           report of the nominating and corporate governance committee and any
                                                                             other evaluations that occurred
board of directors                                                           for more information about our board of directors committee charters
the medtronic board of directors comprises 12 members including our         and memberships visit our corporate governance website
chairman and ceo omar ishrak and our appointed lead independent
director scott donnelly six standing committees of independent directors   executive compensation
oversee our business operations                                             to drive innovation  and ultimately longterm business success  we
 audit                                                                     must attract talented executives with diverse skills and backgrounds who
                                                                             can challenge the status quo we offer competitive benefits alongside cash
 compensation                                                              and equity incentives the boards compensation committee evaluates
                                                                             and approves executive compensation read more about our approach to
 nominating and corporate governance
                                                                             compensation in our proxy statement
 finance and financial risk
 quality
 technology and value creation
                                                                                                                             governance and engagement  32

ethical workplace
                                                                                                                                  code of conduct
we have wellestablished policies and practices to reinforce our culture
of integrity companywide these include ethics and compliance systems                                                                                                                           fy15            fy16             fy17
data analytics and human resources management we look to industry                                                               employees receiving code of conduct                            98              98              97
best practices and benchmarks including ceb to track performance                                                                training and certification
against our peers
                                                                                                                                  new employees receiving code of                                99              99              99
every employee is accountable for compliance with our ethics policies and                                                         conduct training and certification
guidelines managers assess ethical behavior during annual performance
                                                                                                                                  us employees certified as having read                        100             100             100
reviews where an employee does not meet expectations recognition
                                                                                                                                  and understood the code of conduct
awards or monetary bonuses may be withheld
                                                                                                                                  employees terminated for ethical and                           99              125            218
engaging employees in ethics and compliance                                                                                       compliancerelated infractions
                                                                                                                                 fy15 data does not include legacy covidien operations
our global code of conduct is central to our ethics and compliance                                                              
                                                                                                                                  calendar year 2014
program guiding our everyday actions and our interactions with internal                                                         calendar year 2015
                                                                                                                                
                                                                                                                                   calendar year 2016
and external stakeholders                                                                                                       increase from the previous year is primarily due to an expanded definition of termination due to ethical and
                                                                                                                                compliancerelated infractions
the code is available in 22 languages meaning 99 percent of our
employees can read it in their first language we also provide multilingual                                                     in fy17 we conducted an online survey to gauge employee perceptions
training for new employees and those joining medtronic through                                                                  of our performance on ethics and compliance responses from 55000
acquisitions in fy17 97 percent of employees joining through acquisitions                                                     employees revealed that we are doing well at making expectations
received compliance and ethics training within 90 days of the transaction                                                      clear and cultivating open relationships with managers the survey also
                                                                                                                                identified opportunities for improvement by encouraging employees to
employees are retrained on the code of conduct each year everyone at                                                           voice their thoughts and enabling them to feel they can trust colleagues
medtronic including board members must certify their understanding                                                            when raising a concern
of the code and all its requirements annually in fy17 we introduced
specialized ethics training for new managers and updated our training for                                                       during our ethics  integrity week we reinforced the importance of
new employees to promote ethical behavior we asked all employees to                                                           ethical behavior through actions and activities that reached 60 countries
set a personal ethics goal outlining what they will achieve and how                                                            in 11 languages our cardiac and vascular group held a leadership panel
                                                                                                                                event focused on ethics that was open to all its employees more than
                                                                                                                                3500 people attended in person or virtually or watched a recording of
                                                                                                                                the event
                                                                                                                                we also launched more than 100 new ethics circle groups worldwide
                                                                                                                                engaging small groups of employees on specific ethical issues one
                                                                                                                                program in latin america received the medtronic compass award 
                                                                                                                                medtronics highest award for acting with ethics and integrity presented
                                                                                                                                by our ceo the program was recognized for identifying difficult ethical
                                                                                                                                situations employees may encounter and suggesting ways to deal with
                                                                                                                                these more than 2100 people have joined one of our 111 ethics circle
                                                                                                                                groups across 11 countries




4 the inbox is monitored by the administrative staff of the board of directors with pertinent matters being brought to the boards attention for discussion                                        governance and engagement  33

management approach                                                             public policy
the office of ethics and compliance oec oversees monitors and               our government affairs health economics and reimbursement and
implements policies and programs related to our legal compliance and          regulatory affairs teams lead our government engagement activities
ethical obligations its activities include                                    we advocate for public policies that advance our mission and business
                                                                                objectives including those that
 facilitating ethics training and running ethics program analytics
                                                                                 enable therapy innovations
 maintaining our confidential reporting hotline voice your concern line
                                                                                 facilitate access to lifesaving therapies and devices
 leading investigations into alleged misconduct
                                                                                 generate economic value
 supporting compliance teams and leaders across the organization
                                                                                 promote outcomedriven and valuebased healthcare
 developing and monitoring programs and campaigns that increase
   employees ethical awareness                                                  streamline international regulatory practice
 reporting quarterly to the audit committee and at least annually to the      we maintain active membership in medical device trade organizations
   full board via the chief ethics and compliance officer                      globally including advamed apacmed and medtech europe as well
                                                                                as associations in many different countries and us states our ceo
reporting concerns                                                              cochairs the world economic forum global health and healthcare
                                                                                partnership community and is a trustee of the asia society and a board
we encourage employees to seek guidance on ethical issues and raise any
                                                                                member of the usindia business council
concerns about possible legal or ethical violations they can do so via their
manager human resources legal or compliance representatives the              medtronic complies with all relevant country and state laws on disclosure
oec the board of directors email inbox4 or voice your concern line          of political contributions read more about our political contribution policy
the oec processes tracks and oversees all reported concerns from
investigation to resolution in fy17 the oec tracked more than 1200           stakeholder engagement
concerns approximately 75 percent of these related to workplace                we engage and collaborate with a broad spectrum of stakeholders across
conduct the remaining concerns covered issues such as accounting anti        the healthcare system we work together to overcome industrywide
corruption and interactions with healthcare professionals or governments      challenges deliver meaningful innovation improve patient outcomes and
disciplinary action  where appropriate  included coaching changes in         increase global access to healthcare
job responsibilities or title primarily demotion discussion in performance
reviews or in serious cases dismissal during calendar year 2016 a total    stakeholders include patients physicians hospital administrators
of 218 employees were terminated for ethical and compliancerelated             advocacy groups governments nonprofits and nongovernmental
infractions see code of conduct table on previous page                       organizations employees suppliers shareholders regulators and the
                                                                                communities where we operate
if external ethics or compliance issues arise we work with the relevant
authorities to resolve them quickly and effectively                            in fy17 we hosted a global medical device security symposium inviting
                                                                                industry experts to share insights around product security other examples
                                                                                of stakeholder engagement activities are presented throughout this report
                                                                                and on our website




                                                                                                                               governance and engagement  34

operations



medtronic is committed to operating in a safe and                          four regional ehss directors coordinate with local representatives
environmentally sustainable manner our proactive approach                 throughout the company to manage ehss programs and ensure
reduces health and safety hazards in the workplace minimizes              compliance with relevant regulations the directors oversee operations
                                                                           in the following regions
the impact of our operations on the environment and
enhances business efficiency we drive progress and monitor                 americas
environmental performance through our goals to reduce energy                asia pacific
use emissions waste and water use
                                                                            china
our management approach                                                     europe middle east and africa
our global environmental health and safety ehs policy guides our
approach to operating in a safe and environmentally sustainable manner    environmental management systems
it requires us to
                                                                           all our facilities must meet rigorous ehss standards these go beyond
 comply with applicable laws regulations and corporate and             national regulations in many of the countries where we operate
   industry standards
                                                                           medtronic organizations are held to an internal ehss management
 establish ehs goals and targets to measure and continually              system based on the principles of iso 14001 and ohsas 18001 at sites
   improve our performance                                                 with greater potential for ehss risks our environmental management
                                                                           systems are certified to iso 14001 and our safety systems are certified
 integrate ehs into business decisions                                   to ohsas 18001
 minimize our impact on the environment                                  internal audits at major manufacturing facilities and offices worldwide
 create a safe and healthy workplace                                     ensure compliance with our standards and external regulations in fy17
                                                                           site gap assessments helped guide the implementation of our recently
 communicate our policy to stakeholders                                  updated ehs standards
our corporate environmental health safety and sustainability ehss    we participate in the following external sustainability initiatives to enhance
team oversees programs on health and safety ehs compliance               our environmental management and report on our performance
sustainability environmental management and environmental
remediation we provide training to help our ehs professionals implement    cdp for climate disclosure and performance
the policy and accompanying standards at our sites around the world        us environmental protection agencys smartway transportation
                                                                              partnership for sustainable fleet management
                                                                            energy star program for energy efficiency


                                                                                                                                           operations  35

operational footprint                                                                                       energy use and ghg emissions
our environmental priorities are focused on energy use and greenhouse                                       we recognize the risks that climate change poses to society and our
gas ghg emissions regulated and nonregulated waste and water use                                      business we aim to reduce the carbon footprint of our operations by using
                                                                                                            less energy and less carbonintensive energy sources
we have made significant strides toward our 2020 environmental
performance goals over the last four years meeting our targets on energy                                   almost all of our emissions come from the use of electricity natural
use ghg emissions nonregulated waste and water use see table in                                      gas liquefied petroleum gas and fuel oil in fy17 our ghg emissions
fy17 we saw an increase in the rate of regulated waste generated and are                                   totaled 493000 metric tons mt we used approximately 128 million
working to address this across our operations see managing waste                                         megawatthours mwh of energy in fy17 5 percent more than the
                                                                                                            previous year the increase between fy16 and fy17 is largely a result of
                                                                                                            recent acquisitions and increased production despite this we maintained
 2020 environmental performance goals
                                                                                                            our overall 15 percent reduction goal for energy use compared to a fy13
                                         fy15          fy16           fy17           change         2020   baseline when normalizing for our increased revenue during this same
                                                                                    fy13 to          goal   time we further surpassed our ghg emissions goal by achieving a total
                                                                                    fy17                    reduction of 17 percent compared to a fy13 baseline when normalizing
 energy use                              477          424           438          15             15   for our increased revenue
 mwh million revenue
                                                                                                            energy efficiency
 ghg emissions                           185          160           169          17             15
 metric tons                                                                                              wherever feasible we use energyefficient lighting ventilation systems
  million revenue                                                                                         and equipment at our facilities combined with automated building
                                                                                                            controls this helps us achieve significant savings in our energy use
 nonregulated waste                     747          1645         1318         32             15
                                                                                                            emissions and costs energy conservation projects enable us to avoid
 metric tons
                                                                                                            an estimated 25000 mt of ghg emissions per year and cut annual
  billion revenue
                                                                                                            operating costs by approximately 55 million in fy17 we implemented
 regulated waste                         91           92            120           48             10   145 energy conservation projects globally including the extension of our
 metric tons                                                                                              energyefficient lighting installation
  billion revenue
 water use                               128           116            105           23             10   clean and renewable energy
 cubic meters                                                                                             medtronic invests in onsite clean and renewable energy from solar
  million revenue                                                                                         cogeneration and fuel cell technologies we generated more than 64000
 all percentage reduction goals are based on a fy13 baseline year recalculated to account for covidien     mwh of clean and renewable energy in fy17 across 10 sites in ireland italy
acquisition in fy15 all data reflects medtronic and covidien operations

  restated from 2016 integrated report due to internal validation process                                  puerto rico south africa and the united states
                                                                                                            for example our newly deployed fuel cell technology at our northridge
                                                                                                            california site will provide more than 12400 mwh of clean energy
                                                                                                            annually meeting approximately 60 percent of the sites energy needs
                                                                                                            we are evaluating additional opportunities for renewable and clean energy
                                                                                                            installations at sites worldwide including two fuel cells planned at our site
                                                                                                            in north haven connecticut




                                                                                                                                                                             operations  36

fy17 performance
                                                                                                                       regulated waste such as materials and chemicals used in production
 energy use                                                                                                            comprise less than 10 percent of our overall waste yet in fy17 it
                                                        fy15                 fy16               fy17                  increased by 32 percent to a total of 3500 mt primarily due to increased
                                                                                                                       manufacturing we have a robust process to evaluate and address
 mwh                                                    524000              1224000           1282000             significant waste generators and categorize waste types and quantities in
 mwh million revenue                                  296                 424                438                  a concerted effort to meet our 2020 goal
 fy16 data reflects january 2015 covidien acquisition prior year data does not include legacy covidien operations   in addition to managing waste from our daytoday operations we also
                                                                                                                       manage 26 cleanup sites globally these sites are identified by reports
 ghg emissions                                                                                                         showing a possible release of hazardous materials eight of these sites in
                                                                                                                       the united states fall under the comprehensive environmental response
                                                        fy15                 fy16               fy17                  compensation and liability act cercla also known as superfund
 metric tons                                            197000              462000             493000               we also look for opportunities to increase recycling through product
 metric tons million revenue                          111                 160                169                  reclamation and reuse for more information and examples see
                                                                                                                       product stewardship
 fy16 data reflects january 2015 covidien acquisition prior year data does not include legacy covidien operations


 fy17 energy conservation
                                                                                                                       fy17 performance

 energy conservation projects                                                145                                         nonregulated waste

 energy conservation savings mwh                                           49000                                                                                                    fy15              fy16              fy17
 ghg emissions avoided mt                                                  25000                                      metric tons                                                   13277           47456           38567
 operating cost savings  million                                          55                                        metric tons billion revenue                                 747     
                                                                                                                                                                                                         1645            1318
 savings from energy rebates  million                                     18                                       fy16 data reflects january 2015 covidien acquisition prior year data does not include legacy covidien operations
                                                                                                                       
                                                                                                                         restated from 2015 integrated report due to internal validation process
                                                                                                                        restated from 2016 integrated report due to internal validation process

managing waste
                                                                                                                         regulated waste
we strive to avoid waste generation to minimize environmental impact and
reduce costs our landfill diversion initiatives include cutting the amount                                                                                                            fy15              fy16              fy17
of scrap produced during manufacturing making our offices paper free
                                                                                                                         metric tons                                                   1714            2659            3500
and composting food waste in our cafeterias sixty percent of all waste
generated was recycled in fy17                                                                                          metric tons billion revenue                                 97  
                                                                                                                                                                                                         92               120
                                                                                                                        fy16 data reflects january 2015 covidien acquisition prior year data does not include legacy covidien operations
we reduced the amount of nonregulated office and cafeteria waste                                                      
                                                                                                                         restated from 2015 and 2016 integrated report due to internal validation process
generated from our facilities by 19 percent in fy17 to approximately                                                    restated from 2016 integrated report due to internal validation process

38600 mt we achieved our 2020 goal to reduce nonregulated waste
intensity by 15 percent twice over with a total reduction of 32 percent
compared to a fy13 baseline




                                                                                                                                                                                                                        operations  37

 recycling
                                                        fy15                 fy16               fy17
 metric tons                                            7667    
                                                                             28207              25435
  recycled                                             51                   56                  60
 fy16 data reflects january 2015 covidien acquisition prior year data does not include legacy covidien operations

  restated from 2015 integrated report due to internal validation process



water
although our operations do not consume a significant amount of water we
recognize the importance of water to local communities and ecosystems
we aim to minimize our water use by improving the efficiency of
production processes landscape and irrigation systems and heating and
cooling systems
in fy17 we used approximately 31 million cubic meters of water worldwide
 8 percent less than the previous year we surpassed our 2020 goal to
reduce water use intensity by 10 percent from a fy13 baseline achieving
a 23 percent reduction overall

fy17 performance

 water use
                                               fy15                    fy16                  fy17
 cubic meters                                  1240867              3340321            3070925
 cubic meters                                 70                      116                    105
  million revenue
 fy16 data reflects january 2015 covidien acquisition prior year data does not include legacy covidien operations

  restated from 2015 integrated report due to internal validation process
 restated from 2016 integrated report due to internal validation process




                                                                                                                       operations  38

employees



our talented and dedicated workforce helps us grow our business               learning and development
by solving pressing medical challenges to improve the lives of                following an employee orientation when individuals join the company we
patients worldwide as part of our mission we recognize the                  offer continued learning and development opportunities throughout their
valuable contribution our employees make and we work to                       career at medtronic
advance their personal and professional growth through learning               more than 570 online learning tools and courses are available including
and development opportunities                                                virtual and inperson workshops webinars and elearning opportunities
                                                                              many supporting tools and resources exist on our performance and
global workforce                                                              career development portal which is aligned to our career development
at the end of fy17 medtronic employed more than 91000 people and            framework we believe in offering not only educations but also
operated in approximately 160 countries during the year we hired more       differentiated exposure opportunities and experiences for continued
than 17000 new employees                                                    career growth in fy17 we invested more than 76 million in employee
                                                                              training and development programs
the data summary provides more detailed data on our workforce
                                                                              our leadership development programs help ensure that leaders are
                                                                              equipped with the skills needed to effectively manage and develop their
investing in our workforce                                                    teams in fy17 we launched several new programs to set consistent
we invest in talent management and leadership development programs            expectations of medtronic leaders and enhance their skillsets
that enhance the expertise and productivity of our employees and enable
                                                                              our leadership programs include
them to achieve their personal goals
                                                                               enrich  assisting new managers in building essential leadership skills
performance and career development                                               more than 1000 managers have participated since the start of the
                                                                                 program in june 2017
in fy17 medtronic launched a new global performance and career
development process the process is made up of three required                  elevate  a nominationbased development program for high
conversations annually between employees and their managers it ensures          potential leaders it is designed to accelerate their skills and strengthen
that employees have the opportunity to discuss career aspirations               the leadership pipeline across the organization during fy17 more than
set goals and review performance with their managers regularly this            200 highpotential managers and senior managers graduated from
integrated approach supports clear and consistent performance and career         the program
management across the company it also establishes a robust framework
for career development and differentiated pay based on both results and the    vice president onboarding  a program that supports the
leadership behaviors demonstrated in pursuit of high performance                successful transition for vice presidents who are new to medtronic
                                                                                 or those promoted to a vice president position for the first time it
our investment in career development and performance management                  aims to familiarize them with the business their team and the
also extends to our supply chain manufacturing direct labor populations         expectations associated with their role during fy17 more than
have unique needs and follow local processes to ensure an effective annual       80 people participated
performance appraisal process
                                                                                                                                              employees  39

employee engagement
                                                                               workforce diversity raceethnicity
we engage our employees to gather valuable feedback on their
experiences at medtronic in fy17 more than 75000 employees took                                                      fy15        fy16        fy17
part in our employee engagement survey  a strong response rate of             minority representation in the united    30         33         33
82 percent the overall engagement score was 74 percent higher than           states excluding puerto rico
the industry average of 65 percent
we performed well in areas such as support for our mission and                creating opportunities for women
contributions to patient safety opportunities for improvement include        in fy17 women made up 344 percent of management or above positions
facilitating reasonable risktaking for innovation and providing employees    globally and represented 47 percent of our new hires
more opportunities to share their voice and see meaningful action as a
result of their feedback                                                     the medtronic womens network supports the gide team in improving
                                                                              our ability to attract retain and advance women employees more than
through the engagement survey managers receive baseline metrics              9000 women are part of the network which operates 90 hubs in 32
and insights to help identify areas of strength and opportunities for         countries in fy18 we plan to launch wise a program specifically to
improvement they work with their teams to develop action plans and           encourage more women to join science and engineering roles
are encouraged to share responsibility for progress throughout the year
                                                                              employee resource groups
inclusion and diversity
                                                                              more than 14000 employees take part in 13 grassrootsdriven employee
we embrace diversity as a key differentiator and accelerator of innovation    resource groups ergs in 32 countries ergs unite around a common
and business performance our ceo executive committee and board             identity and help foster an inclusive culture across the business they
of directors are advocates for inclusion and diversity and have quarterly     partner with the gide team to support recruiting development and
reviews with diversity network leadership teams twentyfive percent of       community involvement efforts related to their focus
our board members are women and 25 percent represent minority groups
                                                                              in fy17 we received external recognition for our inclusive and diverse
the global inclusion diversity and engagement gide team lead our          culture including
efforts to promote diversity and create an inclusive workplace through our
human resources processes and priorities the team provides analysis and       achieving a perfect 100 percent score for the eighth consecutive year
strategic support to help leaders drive measurable progress                     on the human rights campaign corporate equality index

our diversity networks aim to accelerate the careers of women globally         rising four spots in diversityincs top 50 companies for diversity 
and ethnically diverse leaders in the united states while also influencing      ranking 46 out of 1800 participating companies
key business strategies to meet the healthcare needs of the populations        being named the asia societys best employer for promoting asian
they represent we have four diversity networks the global medtronic            pacific american women and best employer for marketing and support
womens network the african descent network the hispanic latino                to the asian pacific american community
descent network and the asian descent network executive committee
members support diversity networks by providing executive sponsorship
including advocating for resources and change across the organization
by 2020 our aspiration is to have women represent 40 percent or more
of our managers and above globally we also aspire for ethnically diverse
talent to represent 20 percent or more of roles in management and above
in the united states

                                                                                                                                             employees  40

employee compensation                                                         we proactively reduce injury risks by reporting significant incidents to
                                                                              management publishing safety alerts and focusing specific programs at
we offer competitive compensation packages based on individual and
                                                                              sites with higher numbers of injuries for example in certain manufacturing
business performance as well as industry benchmarks in each local
                                                                              systems we incorporated ergonomic reviews and an ergonomic playbook
market for information on executive compensation see governance
                                                                              we will expand the playbook in fy18 to include a variety of environmental
and engagement
                                                                              health safety and sustainability ehss considerations
benefits are a valuable part of medtronics total rewards package our
                                                                              we engage operations executives in quarterly reviews of our health and
benefits are flexible affordable and competitive within our industry
                                                                              safety performance at the business group and regional level during fy17
benefits vary by country and comply with all relevant national regulations
                                                                              we achieved a 6 percent improvement in our recordable incident rate
they typically include
                                                                              compared with the previous year and had no workrelated fatalities
 health dental and vision coverage for employees
                                                                              in addition we rolled out 18 updated ehss standards in fy17 and
   and eligible dependents
                                                                              provided corresponding training for all ehss representatives globally we
 retirement plans                                                           also provided site representatives with gap assessment tools to evaluate
                                                                              site performance and opportunities for ongoing improvement in fy18 our
 life and disability insurance                                              internal audit program will continue to audit regulatory requirements and
 paid time off and leaves of absence                                        our revised internal ehss standards

 employee stock purchase program                                            we also invest in employees physical emotional social and financial
                                                                              wellbeing through our global wellness program healthier together
employees can obtain information on benefits through inperson                all employees have access to this program and in fy17 approximately
presentations ondemand webbased tools askhr support and                  43 percent or 38700 employees participated
our virtual benefits counselor alex
                                                                               safety record
recognition
we value our peoples diligence and innovation and believe their efforts                                                                             fy15          fy16           fy17
should be recognized managers and employees can celebrate their               employee injury incident rate             
                                                                                                                                                     050          045           039
colleagues successes through our global recognize program which             employee lostrestricted                                              023          022           021
honors those who model our leadership expectations and help us drive           workday case rate
progress toward our patientcentered mission in fy17 we recognized more
than 77800 employees including 3370 for outstanding ethical behavior       fatalities                                                            1             0              0
                                                                               the number of workrelated injuries or illnesses serious enough to require treatment beyond first aid per 100
                                                                              employees working a full year
safety and wellness                                                           
                                                                                the number of workrelated injuries or illnesses serious enough to cause an employee to miss one or more
                                                                              workdays or to have one or more workdays of restricted duty per 100 employees working a full year
                                                                               fy15 and fy16 data include both legacy medtronic and legacy covidien employees injury rates do not include
ensuring the safety of our employees is a top priority for us                portions of asia eastern eu or latin america sales
we continued to make progress on our 2020 health and safety
improvement goals which include                                              healthier together
 identifying injury trends and reducing injury risk                                                                                                fy15          fy16          fy17
 reducing ergonomicrelated injury rates                                     employees registered on the wellness platform                                       50769        38725
 accelerating global employee training on environmental                     workforce participation rate                                                        57           43
   health and safety requirements                                             historic participation rates were based on questionnaires that are no longer used employee participation is
                                                                              now measured by registration on the wellness platform historic data has been removed
                                                                              
                                                                                medtronics new wellness website launched in fy17 q4 all employees must reregister
                                                                              on the platform which caused a decrease in our overall reported participation rate         employees  41

data summary

 medtronic global workforce                                                                                   global fulltime

                                                              fy15           fy16          fy17                                                                       fy15            fy16            fy17
 total                                                        46368          90549          94834           total                                                       45084           88520            92943
   female                                                     22657          44371          46769           30 and under                                                7967            18043            20013
 asia pacific                                                 4950           12363          13188
                                                                                                               3150                                                       28341           52891            55243
   female                                                     2169           5381           5745
                                                                                                               51 and above                                                8776            16546            17687
 canada                                                       792             1544           1634
                                                                                                               female                                                   21530           42687            45181
   female                                                     495             900             956
                                                                                                                 asia pacific                                              2113            5299             5665
 europecentral asiamiddle eastafrica                       9754           17820          18854             canada                                                    484              896               947
   female                                                     5069           9149           9562              e
                                                                                                                  uropecentral asiamiddle eastafrica                   4192            7939             8386
 latin america                                                3786           16425          17621             latin america                                             2628            10013            10971
                                                                                                                 us and puerto rico                                      12113           18540            19212
   female                                                     2628           10019          10983
                                                                                                               employee population data expressed here may vary from our 2017 10k form depending on the time of year in
 us and puerto rico                                         27086          42397          43537          which the data was gathered
                                                                                                              
                                                                                                                fy15 does not include legacy covidien employees
   female                                                     12296          18922          19523           1041 records have outofbound values so are not included in age breaks 595 records do not specify gender
                                                                                                              
                                                                                                                 478 records have outofbound values so are not included in age breaks 123 records do not specify gender
 employee population data expressed here may vary from our 2017 10k form depending on the time of year in    numbers by region are based on female employees only
which the data was gathered

  fy15 does not include legacy covidien employees
 595 records do not specify gender

   123 records do not specify gender


 employment type                                                                                            global parttime

                                                                                            fy17                                                                           fy15            fy16            fy17

 support staff                                                                              42531             total                                                       1284            2029             1891
   female                                                                                   25142             30 and under                                                66               228               172
 professional                                                                               41368             3150                                                       985              1373             1291
   female                                                                                   17750             51 and above                                                233              427               428
 management                                                                               9816              female                                                   1127            1684             1588
                                                                                                                 asia pacific                                              56               82                80
   female                                                                                   3429
                                                                                                                 canada                                                    11               4                 9
 vps and higher                                                                             528                   uropecentral asiamiddle eastafrica
                                                                                                                 e                                                         877              1210             1176
   female                                                                                   141                  latin america                                             0                6                 12
                                                                                                                 us and puerto rico                                      183              382               311
 employee population data expressed here may vary from our 2017 10k form depending on the time of year
when the data was gathered                                                                                    employee population data expressed here may vary from our 2017 10k form depending on the time of year in

  591 employees do not have a job category designation                                                       which the data was gathered
 management  managers senior managers directors and senior directors                                   
                                                                                                                fy15 does not include legacy covidien employees
                                                                                                               1041 records have outofbound values so are not included in age breaks 595 records do not specify gender
                                                                                                              
                                                                                                                 478 records have outofbound values so are not included in age breaks 123 records do not specify gender
                                                                                                               numbers by region are based on female employees only
                                                                                                                                                                                                          employees  42

 new employee hires                                                                                              employee turnover voluntary and involuntary
                                                           fy15            fy16          fy17                                                                         fy15             fy16            fy17
 total                                                  5407            16026          17408                total                                                 4453             13509            15022
 30 and under                                              2384            7344           9591                 30 and under                                          1174             5313             6649
 3150                                                     2702            6673           6801                 3150                                                 2492             6216             6295
 51 and above                                              321              867             1016                 51 and above                                          787               1980             2078
 female     
                                                           2574            7266           8234                 female                                             2236             6873             7167
   asia pacific                                            431              1189           1184                   asia pacific                                        292               816               826
   canada                                                  29               132             126                     canada                                              18                181               128
   europecentral asiamiddle eastafrica                 440              1255           1350                  europecentral asiamiddle eastafrica              517               1073             1312
   latin america                                           255              2027           2894                   latin america                                       383               2455             2462
   us and puerto rico                                    1419            2663           2680                   us and puerto rico                                1026             2348             2439
 employee population data expressed here may vary from our 2017 10k form depending on the time of year in   
                                                                                                                fy15 does not include legacy covidien employees
which the data was gathered                                                                                   105 records have values out of bounds for example age0 81 records do not specify gender

  fy15 does not include legacy covidien employees                                                            
                                                                                                                 1440 records have values out of bounds for example age0 674 records do not specify gender
 1142 records have values out of bounds for example age0 672 records do not specify gender            numbers by region are based on female employees only

   1510 records have values out of bounds for example age0 578 records do not specify gender
 fiscal years 2015 did not include employees who were hired and terminated within the same year

    numbers by region are based on female employees only




                                                                                                                                                                                                           employees  43

about this report



our reporting reflects the way we do business  integrating social           assurance and forwardlooking statements
environmental ethical and financial performance this is our fourth
                                                                              we have not sought independent verification of this report and we have
annual integrated performance report comprising both financial and
                                                                              practices in place to internally validate the data
nonfinancial information
                                                                              any forwardlooking statements are subject to risks and uncertainties
the report covers issues that are most material to our business and our
                                                                              such as those described in medtronics periodic reports on file with the
stakeholders these are summarized in the sustainability risks and
                                                                              securities and exchange commission sec actual results may differ
opportunities section
                                                                              materially from anticipated results
the report was prepared in accordance with the g4 core guidelines of the
global reporting initiative gri an internationally recognized framework    further information
for sustainability reporting the content is also informed by the reporting
requirements of the sustainability accounting standards board sasb for      for additional business and sustainability information please refer to our
medical equipment and supplies and the dow jones sustainability index       sec filings including form 10k and proxy filings as well as press releases
                                                                              and our cdp disclosure

scope and data                                                                we value our stakeholders views to provide feedback or request further
                                                                              information please email integratedreportmedtroniccom
unless otherwise stated all performance data covers our fiscal year 2017
fy17 from april 29 2016 through april 28 2017 our previous report for
fy16 was published in november 2016
this report includes data from medtronic plc and all of its consolidated
subsidiaries environmental health and safety data covers our
manufacturing and research and development facilities
all reported data are best estimates some entities are omitted from
metrics where their impact on overall data is less than 10 percent such
exclusions are noted throughout the report
all financial information is reported in us dollars




                                                                                                                                        about this report  44

integration index



integrated reporting at medtronic
this report provides an overview of how sustainability is integrated in medtronics business the index below highlights some of the most important ways that
our social environmental and ethical performance is tied to our business success

 section                    integration touchpoint                                                                          subsection

 sustainability             sustainability risk management                                                                  sustainability management
 risks and opportunities
                            business continuity risk management                                                             reducing sustainability risk

                            meeting customer expectations through sustainability performance                                creating opportunities

                            responding to investor requirements                                                             creating opportunities

 economic contributions     driving revenue growth in emerging markets                                                      financial performance
 to society
                            supporting local communities through operational costs                                          expenditures

                            aligning business with healthcare needs through strategic acquisitions and investments          acquisitions and investments

                            philanthropy as a percentage of pretax profits                                                 philanthropy

                            product donations                                                                               philanthropy

 access                     investing in rd to spur new product service and therapy innovation                           therapy innovation

                            pursuing valuebased healthcare and managed services for improved clinical outcomes and         economic value
                            value alignment

                            addressing affordability through pricing models                                                 economic value

                            building the capacity of local infrastructure healthcare providers and patients to increase   expanding global access
                            the effective use of our products and services

                            addressing healthcare needs worldwide through innovative business models                        expanding global access



                                                                                                                                             integration index  45

section               integration touchpoint                                                                        subsection

product quality       expanding our commitment to product quality through supplier engagement                       responsibility for quality

                      enhancing postmarket surveillance to improve patient outcomes                                product use and performance

                      monitoring our facilities to avoid disruptions to our operations and supply chain             maintaining quality facilities

                      maintaining high ethical standards for animal research to support our brand reputation        preclinical research
                      and license to operate

product stewardship   reducing waste and saving costs                                                               our approach

responsible           supplier quality management to avoid errors that can impact patient health and                supplier quality management
supply management     damage reputation

                      how our global human rights and labor standards and supplier diversity programs support       responsible supply management
                      our brand reputation and license to operate

ethics in sales       reducing risk in distribution channels                                                        ethical business conduct
and marketing
                      protecting patient privacy and health data                                                    customer data security

governance and        ethical conduct as an integral part of our credibility and success                            ethical workplace
engagement
                      advocating for public policies that advance our mission and business objectives               public policy

operations            environmental health safety and sustainability ehss management to improve               our management approach
                      operational efficiencies and save costs

employees             investing in our employees personal and professional development to drive business success   investing in our workforce

                      building inclusion and diversity as an enabler of innovation                                  inclusion and diversity




                                                                                                                                      integration index  46

nongaap
financial measures


this report contains financial measures including free cash flow figures defined as operating cash flows less property
plant and equipment additions revenue growth rates and diluted eps figures on a constant currency basis and as
adjusted for the extra week in fiscal year 2016 constant currency growth measures the change in revenue between
current and prior year periods using average exchange rates in effect during the applicable prior year period these
figures are nongaap financial measures under applicable sec rules and regulations
management believes that referring to constant currency growth rates is a useful way to evaluate the underlying
performance of medtronics sales medtronic generally uses nongaap financial measures to facilitate managements
review of the operational performance of the company and as a basis for strategic planning nongaap financial
measures should be considered supplemental to and not a substitute for financial information prepared in accordance
with generally accepted accounting principles gaap the companys definition of these nongaap measures may not
be the same or similar to measures presented by other companies
nongaap financial measures exclude the effect of items that will increase or decrease the companys reported results
of operations therefore management strongly encourages investors to review the companys consolidated financial
statements and publicly filed reports in their entirety




                                                                                                                            nongaap financial measures  47

 medtronic plc
 fy17 net income and diluted eps gaap to nongaap reconciliations
 unaudited in  million except per share data

                                                                                        fiscal year ended april 28 2017

                                                                                        income before provision                net income attributable                 diluted                                 effective
                                                                                        for income taxes                       to medtronic                            eps                                    tax rate

 gaap                                                                                   4602                                 4028                                  289                                   126
 nongaap adjustments
     impact of inventory stepup                                                      38                                    24                                     002                                    368
     special charges                                                                 100                                   63                                     005                                    370
     restructuring charges net                                                         373                                   272                                    020                                    271
     certain litigation charges                                                         300                                   190                                    014                                    367
     acquisitionrelated items                                                       230                                   156                                    011                                    322
     amortization of intangible assets                                                  1980                                 1460                                  105                                    263
     certain tax adjustments net                                                                                         202                                    015                                    
 nongaap                                                                               7623                                 6395                                  460                                   162
     foreign currency impact                                                                                                                                           017
 constant currency adjusted                                                                                                                                            477
 see description of nongaap financial measures contained on page 47 of this report

  the data in this schedule has been intentionally rounded to the nearest 001 and therefore may not sum
 nongaap adjustments relate to charges or benefits that management believes may or may not recur with similar materiality or impact on results in future periods

   represents amortization of stepup in fair value of inventory acquired in connection with the heartware acquisition
 the charge represents a contribution to the medtronic foundation

    integrationrelated costs incurred in connection with the covidien acquisition and charges incurred in connection with the pending divestiture of a portion of our patient monitoring and recovery division to cardinal health
 the net charge primarily relates to the tax effect from the recognition of the outside basis difference of certain subsidiaries which are included in the expected divestiture of a portion of our patient monitoring and recovery division
to cardinal health certain tax charges recorded in connection with the redemption of an intercompany minority interest and the resolution of various tax matters from prior periods




                                                                                                                                                                                                       nongaap financial measures  48

 medtronic plc
 fy17 net income and diluted eps gaap to nongaap reconciliations
 unaudited in  million except per share data

                                                                                       fiscal year ended april 29 2016

                                                                                       income from operations                 net income attributable                 diluted                                effective
                                                                                       before taxes                           to medtronic                            eps                                   tax rate

 gaap                                                                                  4336                                 3538                                  248                                  184
 nongaap adjustments
     impact of inventory stepup                                                     226                                    165                                     012                                   270
     special charges                                                                70                                     44                                      003                                   371
     restructuring charges net                                                        299                                    221                                     015                                   261
     certain litigation charges                                                        26                                     17                                      001                                   346
     acquisitionrelated items                                                         283                                    212                                     015                                   251
     amortization of intangible assets                                                 1931                                  1467                                   103                                   240
     loss on previously held forward starting interest                                 45                                     29                                      002                                   356
     swap rates
     debt tender premium                                                               183                                    118                                     008                                   355
     certain tax adjustments net                                                                                         417                                     029                                   
 nongaap                                                                              7399                                 6228                                  437                                  158
 yearoveryear percent change
     gaap                                                                                                                                                             17
     nongaap                                                                                                                                                         5
     constant currency adjusted nongaap                                                                                                                          9
 see description of nongaap financial measures contained on page 47 of this report

  the data in this schedule has been intentionally rounded to the nearest 001 and therefore may not sum
 nongaap adjustments relate to charges or benefits that management believes may or may not recur with similar materiality or impact on results in future periods

   represents amortization of stepup in fair value of inventory acquired in connection with the covidien acquisition
 the impairment of debt investment

    primarily related to us income tax expense resulting from the companys completion of an internal reorganization of the ownership of certain legacy covidien businesses that reduced the cash and investments held by medtronics
uscontrolled nonus subsidiaries also includes a benefit related to the establishment of a deferred tax asset on the tax basis in excess of book basis of a wholly owned us subsidiary of which the company disposed
 due to its 5253 week fiscal year calendar the company had an additional selling week in the first quarter of fiscal year 2016 while it is difficult to calculate an exact impact from the extra week the company estimates an 008
to 010 benefit to nongaap diluted earnings per share eps in the first quarter of fiscal year 2016 the company estimates that adjusting for the extra week nongaap earnings diluted eps and operating margin increases were
approximately 8 to 9 percent approximately 11 to 12 percent and approximately 1 percent respectively on a constant currency constant week basis when compared to the prior fiscal year




                                                                                                                                                                                                     nongaap financial measures  49

 medtronic plc
 reconciliation of operating cash flow to free cash flow
 unaudited in  million

                                                                                                                                   fy15                                   fy16                                  fy17

 net cash provided by operating activities                                                                                         4902                                 5218                                6880
 additions to property plant and equipment                                                                                       571                                  1046                               1254
 free cash flow                                                                                                                   4331                                 4172                                5626
 investors should consider these nongaap measures in addition to and not as a substitute for financial performance measures prepared in accordance with us gaap

  free cash flow represents operating cash flows less property plant and equipment additions




 fy17 reconciliation of worldwide geographic reported growth to
 worldwide geographic constant currency growth
 unaudited in  million

                                                           fiscal year as reported                                                                        fiscal year constant currency adjusted

                                                           fy16                           fy17                            reported                        currency                       fy17                            constant
                                                           total                          total                           growth                        impact                         total                           currency
                                                                                                                                                          on revenue                                                     growth

 us                                                      16422                        16663                         1                                                            16663                         1
 nonus developed                                        8708                         9085                          4                              44                             9041                          4
 emerging markets                                          3703                         3962                          7                              78                           4040                          9
 total                                                     28833                        29710                         3                              34                           29744                         3
 us includes the united states and us territories nonus developed markets include japan australia new zealand korea canada and the countries of western europe emerging markets include the countries of the middle east
africa latin america eastern europe and the countries of asia that are not included in the nonus developed markets as previously defined

  constant currency growth a nongaap financial measure measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period
 fiscal year 2016 was a 53week year with the extra week included in the first quarter results while it is difficult to calculate the impact of the extra week the company estimates that the extra week impact on worldwide fiscal year 2016
first quarter revenue was approximately 450 million excluding the approximately 450 million from fy16 total revenue would result in approximately 5 percent overall growth and low double digit emerging markets growth in each case on
a constant currency constant week basis




                                                                                                                                                                                                      nongaap financial measures  50

 medtronic plc
 reconciliation of diluted eps to nongaap eps and dividend payout ratio unaudited
                                                                                                                         fy15                                    fy16                                    fy17
 diluted eps                                                                                                             241                                   248                                   289
 nongaap adjustments
    impact of inventory stepup                                                                                          041                                  012                                  002
    restructuring charges net                                                                                           016                                    015                                    020
    acquisitionrelated items                                                                                            039                                    015                                    011
    amortization of intangible assets                                                                                    049                                    103                                    105
    certain litigation charges                                                                                           002                                    001                                    014
    certain tax adjustments net                                                                                         031   
                                                                                                                                                                 029                                015
    special charge gain net                                                                                           002                            003                               005
    loss on previously held forward starting interest rate swaps                                                                                                002                              
    debt tender premium                                                                                                                                         008                                    
    impact of product technology upgrade commitment                                                                      006                                                                    
    impact of acquisition on interest expense                                                                            004                                                                    
 nongaap eps                                                                                                            428                                   437                                    460
    currency impact                                                                                                                                              047                                    017
 adjusted nongaap eps                                                                                                                                           484                                   477
 dividend per share                                                                                                      122                                   152                                   172
 dividend payout ratio                                                                                                   40                                     63                                     69
    impact of nongaap adjustments                                                                                       10                                    27                                    30
 dividend payout ratio nongaap basis                                                                                   30                                     36                                     39
investors should consider these nongaap measures in addition to and not as a substitute for financial performance measures prepared in accordance with us gaap
 the data in this schedule has been intentionally rounded to the nearest 001 and therefore may not sum

  nongaap adjustments relate to charges or gains that management believes may or may not recur with similar materiality or impact on results in future periods
 represents amortization of stepup in fair value of inventory acquired in connection with the heartware acquisition

   represents amortization of stepup in fair value of inventory acquired in connection with the covidien acquisition
 integrationrelated costs incurred in connection with the covidien acquisition and charges incurred in connection with the pending divestiture of a portion of our patient monitoring  recovery division to cardinal health

    the net charge primarily relates to the tax effect from the recognition of the outside basis difference of certain subsidiaries which are included in the expected divestiture of a portion of our patient monitoring  recovery division to
cardinal health certain tax charges recorded in connection with the redemption of an intercompany minority interest and the resolution of various tax matters from prior periods
 primarily relates to us income tax expense resulting from the companys completion of an internal reorganization of the ownership of certain legacy covidien businesses that reduced the cash and investments held by medtronics
uscontrolled nonus subsidiaries also includes a benefit related to the establishment of a deferred tax asset on the tax basis in excess of book basis of a wholly owned us subsidiary of which the company disposed

     primarily relates to a 329 million tax expense for anticipated resolution of the kyphon acquisitionrelated issues with the irs
 the charge represents a contribution to the medtronic foundation

      the impairment of a debt investment
 special gain includes 64 million aftertax charitable contribution made to the medtronic foundation 25 million aftertax gain on divestiture recognized in connection with the sale of the microfrance product line and 62 million
aftertax net gain recognized in connection with the sale of a certain equity method investments

       relates to losses incurred from the unwinding of forward starting interest rate swaps which were previously entered into in advance of a planned debt issuance that was no longer expected post the internal reorganization
 probable and reasonably estimable charges related to a crhf global comprehensive program for home based monitors due to industry conversion from analog to digital technology

        represents the incremental interest expense incurred to hold 17 billion of debt from december 10 2014 through the end of the third quarter of fy15 on december 10 2014
medtronic inc issued 17 billion of debt to finance in part the cash component of the covidien acquisition consideration including the payment of certain transaction and financing
expenses and for working capital and general corporate purposes                                                                                                                                          nongaap financial measures  51

 medtronic plc
 reconciliation of net income to nongaap net income unaudited in  million
                                                                                                                          fy15                                     fy16                                    fy17
 gaap net income attributable to medtronic                                                                                2675                                   3538                                  4028
 nongaap adjustments
     impact of inventory stepup                                                                                          455                                    165                                   24
     restructuring charges net                                                                                           180                                      221                                     272
     acquisitionrelated items                                                                                            433                                      212                                     156
     amortization of intangible assets                                                                                    538                                      1467                                   1460
     certain litigation charges                                                                                           27                                       17                                      190
     certain tax adjustments net                                                                                         349  
                                                                                                                                                                   417                                 202
     special charge gain net                                                                                           23                               44                                 63
     loss on previously held forward starting interest rate swaps                                                                                                 29                                
     debt tender premium                                                                                                                                          118                                     
     impact of product technology upgrade commitment                                                                      61                                                                       
     impact of acquisition on interest expense                                                                            49                                                                       
 nongaap net income attributable to medtronic                                                                            4744                                   6228                                  6395
 dividends                                                                                                                1337                                    2139                                   2376
 share repurchases net                                                                                                   1271                                    2339                                   3116
 total payout ratio                                                                                                       97                                      127                                    136
     impact of nongaap adjustments                                                                                       42                                     55                                    50
 total payout ratio nongaap basis                                                                                       55                                      72                                     86
investors should consider these nongaap measures in addition to and not as a substitute for financial performance measures prepared in accordance with us gaap
 the data in this schedule has been intentionally rounded to the nearest 001 and therefore may not sum

  nongaap adjustments relate to charges or benefits that management believes may or may not recur with similar materiality or impact on results in future periods
represents amortization of stepup in fair value of inventory acquired in connection with the heartware acquisition

   represents amortization of stepup in fair value of inventory acquired in connection with the covidien acquisition
 integrationrelated costs incurred in connection with the covidien acquisition and charges incurred in connection with the pending divestiture of a portion of our patient monitoring  recovery division to cardinal health

    the net charge primarily relates to the tax effect from the recognition of the outside basis difference of certain subsidiaries which are included in the expected divestiture of a portion of our patient monitoring  recovery division
to cardinal health certain tax charges recorded in connection with the redemption of an intercompany minority interest and the resolution of various tax matters from prior periods
 primarily relates to us income tax expense resulting from the companys completion of an internal reorganization of the ownership of certain legacy covidien businesses that reduced the cash and investments held by
medtronics uscontrolled nonus subsidiaries also includes a benefit related to the establishment of a deferred tax asset on the tax basis in excess of book basis of a wholly owned us subsidiary of which the company disposed

     primarily relates to a 329 million tax expense for anticipated resolution of the kyphon acquisitionrelated issues with the irs
 the charge represents a contribution to the medtronic foundation

      the impairment of a debt investment
 special gain includes 64 million aftertax charitable contribution made to the medtronic foundation 25 million aftertax gain on divestiture recognized in connection with the sale of the microfrance product line and 62 million
aftertax net gain recognized in connection with the sale of a certain equity method investments

       relates to losses incurred from the unwinding of forward starting interest rate swaps which were previously entered into in advance of a planned debt issuance that was no longer expected post the internal reorganization
 probable and reasonably estimable charges related to a crhf global comprehensive program for home based monitors due to industry conversion from analog to digital technology

        represents the incremental interest expense incurred to hold 17 billion of debt from december 10 2014 through the end of the third quarter of fy15 on december 10 2014 medtronic inc issued 17 billion of debt to finance
in part the cash component of the covidien acquisition consideration including the payment of certain transaction and financing expenses and for working capital and general corporate purposes


                                                                                                                                                                                                    nongaap financial measures  52

